Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-24-2020 10:00 AM

The role of the Leucine-Rich (LeuR) domain of Rho Guanine
Nucleotide Exchange Factor (RGNEF) in the regulation of
amyotrophic lateral sclerosis (ALS) associated protein TAR DNAbinding protein of 43 KDa (TDP-43)
Hind Amzil, The University of Western Ontario
Supervisor: Strong, Michael J., The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Pathology and Laboratory Medicine
© Hind Amzil 2020

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Laboratory and Basic Science Research Commons, Molecular and Cellular Neuroscience
Commons, and the Molecular Biology Commons

Recommended Citation
Amzil, Hind, "The role of the Leucine-Rich (LeuR) domain of Rho Guanine Nucleotide Exchange Factor
(RGNEF) in the regulation of amyotrophic lateral sclerosis (ALS) associated protein TAR DNA-binding
protein of 43 KDa (TDP-43)" (2020). Electronic Thesis and Dissertation Repository. 7323.
https://ir.lib.uwo.ca/etd/7323

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
The presence of neuronal cytoplasmic inclusions (NCIs) composed of RNA-binding proteins
(RBPs) and neurofilaments is considered to be ALS’s neuropathological hallmark. RGNEF has
been previously shown to interact with TDP-43 and to have a regulatory effect on the expression
levels of NEFL mRNA and NFL protein in vitro. Here, I examined the mechanism of the
RGNEF N-terminus, leucine-rich domain (LeuR) domain’s interaction with TDP-43. I observed
that the minimal domain required is 110 amino acids (LeuR110), that the Ankyrin domain
adjacent to LeuR110 does not participate, and that LeuR110 forms of a high molecular weight
complex with TDP-43 in vitro consistent with the co-aggregation of LeuR242 and TDP-43 in
double transgenic drosophila melanogaster. I also observed that RGNEF interacts directly with
and destabilizes the TARDBP mRNA 3’UTR. These findings support that RGNEF interacts with
TDP-43 through the formation of a high molecular weight complex and the down-regulation of
its expression.
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Summary for Lay audience
Amyotrophic Lateral Sclerosis (ALS) is a progressive, adult-onset disease characterized by the
degeneration of motor neurons. In the cytoplasm of neuronal cells, the buildup of RNA-binding
proteins (RBPs), neurofilaments and other proteins are considered to be the disease’s hallmark.
Among these proteins, Rho guanine nucleotide exchange factor (RGNEF) has been identified as
a key element in the development of ALS, where it accumulates in the cytoplasm of motor
neurons. Previously, RGNEF has been shown to interact with another protein TDP-43 and to
regulate a neurofilament protein NFL. Here, I focused on the mechanism of interaction between
TDP-43 and a region of RGNEF, leucine-rich (LeuR). I observed that a minimal domain of LeuR
interacts with TDP-43 by forming a complex of proteins, consistent with our observations in the
brain and eye tissue of an ALS fly model. In addition to the interacting mechanism, I studied the
role of RGNEF in the regulation of TDP-43. I observed that in the presence of the LeuR, there is
a downregulation in TDP-43 levels. By defining the role of the interaction between two ALSassociated RBPs, RGNEF and TDP-43, we can get a step further into identifying a potential
therapeutic target in ALS.
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Chapter 1
1.1 Clinical aspects of ALS
1.1.1 History and description of ALS
Amyotrophic Lateral Sclerosis (ALS) is a progressive, adult-onset neurodegenerative disease
first described by French neurologist Jean-Martin Charcot in 1869 (Charcot & Joffroy, 1869).
Considered the founder of modern neurology, he revolutionized the field by coupling clinical
observations and pathological findings associated with various neurological diseases that would
allow for a more accurate classification. Through studies conducted on the first ALS cases
from1865 to 1869, alongside his pupil then colleague Alix Joffroy, Charcot observed that lesions
of the anterior horn of the spinal cord resulted in paralysis accompanied by atrophy of muscle,
whereas the lesions in the lateral column of the spinal cord resulted in progressive paralysis and
no atrophy of muscles, thus establishing clinicopathological correlate of lower motor neuron
(LMN) vs upper motor neuron (UMN) pathology (Charcot & Joffroy, 1869).
These observations supported Charcot’s hypothesis that the various clinical outcomes of
this motor neuron disease are a result of the location of the lesions. It wasn’t until 1874 that the
name amyotrophic lateral sclerosis was associated with motor neuron disease in Charcot’s
publication “Œuvres complètes” in which he described the unique features of ALS. Firstly, he
noted that the paralysis of the upper limbs occurred without loss of sensation, shortly thereafter
the legs became affected with atrophy of the muscles of the paralyzed limbs. With disease
progression, these features worsened and were accompanied by the apparition of bulbar
symptoms. The progress of the pathology through each phase was rapid and death occurred 2 to
3 years from the onset of the bulbar symptoms on average (Charcot, 1874).
Since then, neurologists around the world still rely on similar clinical features when
describing patients with ALS (Rowland & Shneider, 2001) (Brown & Al-Chalabi, 2017) such
that the progressive loss of upper (UMN) and lower (LMN) motor neurons in the brain and the
spinal cord is a defining characteristic of the pathology.
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1.1.2 Diagnosis and epidemiology
Over the past two decades, physicians have been using El Escorial Criteria and its revised
version as a diagnostic tool (Brooks, 1994) (Brooks, Miller, Swash, & Munsat, 2000). These
criteria are based on a combination of features and an algorithm for diagnostic certainty. Core
features of the criteria include the history, physical and neurological examinations supported by
electrophysiological studies to assess the degree of LMN involvement, and neuroimaging when
appropriate to exclude other diseases and neuropathology. The concept of progression is also
critical (Brooks, 1994). These criteria were subsequently modified to increase the sensitivity of
ALS diagnosis (Carvalho, et al., 2008). These revised criteria (the Awaji criteria) increased the
weighting applied to the neurophysiological data alongside the clinical observations as a single
dataset to decrease the number of ALS false positives (Zarei, et al., 2015). This modification
increased the sensitivity of probable or definite ALS diagnoses by over 20% (Costa, Swash, &
Carvalho, 2012).
Because the initial symptoms of ALS are highly nonspecific and can mimic those of other
muscle wasting diseases, misdiagnosis in early stages of the disease is very common and often
leads to delays in ALS diagnosis. Since there are no valid diagnostic ALS biomarkers, the
diagnosis remains based on clinical symptoms and electrophysiology that require spreading over
time (Longinetti & Fang, 2019).
While the clinical presentation of ALS is heterogenous because of the various motor
neuron populations involved, typically patients present with motor neuron lesions serving bulbar
functions and limbs (Zarei, et al., 2015) (Brown & Al-Chalabi, 2017). Typically, these lesions
result in weakness of the limbs and bulbar musculature. In general, most patients show an initial
limb-onset (Brooks, 1996) with features including muscle stiffness and spasticity, fasciculation,
weight loss, muscle cramps and as the degeneration progresses, muscle atrophy (Brown & AlChalabi, 2017) (Magnussen & Glass, 2017). The pathology later progresses toward the bulbar
regions (Brooks, 1996). However, about a third of ALS cases have an early bulbar-onset, where
the affected regions have a predominantly LMN involvement and the patients present with
symptoms such as difficulty swallowing, chewing and speaking (Brown & Al-Chalabi, 2017)
(Grad, Rouleau, Ravits, & Cashman, 2017). The disease progresses as the motor neurons of the
brain and the spinal continue to degenerate affecting muscles of the limbs, oropharynx, tongue
and eventually the diaphragm. In the later stages of ALS, the respiratory muscles are weakened,
2

which eventually leads to respiratory failures (Zarei, et al., 2015). However, ALS does not seem
to affect the oculomotor neurons or those of Onuf’s nucleus supplying bladder function (Brown
& Al-Chalabi, 2017).
While the presence of motor dysfunction remains core to the diagnosis of ALS, there is
an increasing awareness of nonmotor manifestations of the disease. The finding was first
highlighted in the early 1980s by Arthur J. Hudson who noted that a proportion of ALS patients
also demonstrated other neurological disorders including dementia, Parkinson’s and other
behavioral deficits (Hudson, 1981). Since then, the more contemporary literature has been
defining ALS as a multisystem disorder with a subgroup of ALS patients showing symptoms of
frontotemporal dementia (FTD) (Strong, et al., 2009) (Strong, et al., 2017). A prospective study
conducted by the Miller group on 2002 show that 14% of patients diagnosed with FTD were later
diagnosed with ALS whereas 36% presented with features of ALS and then developed ALS
(Lomen-Hoerth, Anderson, & Miller, 2002). The pathological characterization of FTD in ALS
patients shows frontal and temporal cortical degeneration with neuronal loss and spongiform
degeneration (Hudson, 1981). The behavioral syndrome associated with FTD detected in ALS
patients includes significant alterations of personality and social conduct while the memory is
relatively spared (Strong, et al., 2009) (Strong, et al., 2017).
The average lifespan from disease onset is 3 to 5 years with respiratory failure as the most
common cause of death (Yedavalli, Patil, & Shah, 2018). The incidence rate is estimated at
1.8/100,000 people per year with a mean prevalence of 3.4/100,000 in North America (Grad,
Rouleau, Ravits, & Cashman, 2017). While over ninety percent of ALS cases are classified as
sporadic (sALS), two other variants of ALS exist and are classified as follows: familial ALS
(fALS) linked to specific genetic inheritance of multiple ALS-associated genes and a previously
hyperendemic focus in the Kii Peninsula, Guam and Papua New Guinea known as the Western
Pacific variant (Sorarù, et al., 2009).

1.2 ALS-associated genes
While over 90% of ALS cases are classified as sporadic, approximately 10% are associated with
a family history. Approximately half of these have an autosomal dominant transmission, while
recessive (Andersen & Al-Chalabi, 2011) or X-linked (Kennedy, Alter, & Sung, 1968) (Harding,
Thomas, Bradbury, Morgan-Hughes, & Ponsford, 1982) are less common. However, a clear
3

distinction between these two variants of ALS remains controversial if we follow the Mendelian
inheritance definition. Indeed, the gene mutations identified in fALS cases have also been
observed in sALS (Al-Chalabi, et al., 2013).
Although not all causative, mutations in over 25 genes have been associated with ALS
(Andersen & Al-Chalabi, 2011). A genome-wide association study looking into the whole exome
sequencing of a vast number of individuals allowed scientists to create a database of ALS genes
with their corresponding clinical phenotype (Abel, Powell, Andersen, & Al-Chalabi, 2012).
Amongst those genes known to be causative of ALS, a subset are more commonly observed,
including superoxidase dismutase 1 (SOD1) (Rosen et al., 1993), TAR DNA-binding protein 43
(TARDBP) (Sreedharan, et al., 2008) (Davidson, et al., 2016), fused in sarcoma (FUS) (Deng, et
al., 2010) and Chromosome 9 open reading frame 72 (C9orf72) (DeJesus-Hernandez,
Mackenzie, Boeve, & al., 2011) (Renton, et al., 2011).
As indicated in table 1, there are also an increasing number of genetic mutations observed
in association with ALS in which the mutation is considered to be rare or not causative, but
rather disease modifying. Among those, mutations are observed in optineurin (OPTN)
(Maruyama, et al., 2010), TATA-binding protein-associated factor 15 (TAF-15), Ewing sarcoma
breakpoint region 1 (EWSR1) (Couthouis J. , et al., 2012), rho guanine nucleotide exchange
factor (RGNEF) (Keller, et al., 2012) (Droppelmann, et al., 2013) (Droppelmann, Keller,
Campos-Melo, Volkening, & Strong, 2013), and intermediate filaments (neurofilament NEFH
and peripherin) (Al-Chalabi, et al., 1999) (Wong, He, & Strong, 2000) (Gros-Louis, et al., 2004).
While the pathobiology of ALS is complex and heterogenous, the study of its genetic
variants helped identify three molecular categories through which the disease is induced. These
include alterations in protein homeostasis, cytoskeletal dynamics and RNA homeostasis (Brown
& Al-Chalabi, 2017). In the next section, I will discuss the major ALS-associated proteins
identified in the literature and their role in the pathobiology of ALS.
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Table 1. ALS-associated genes
ALS pathology

ALS-associated

process

gene
RNA TARDBP

metabolism FUS

TAF15

Inheritance

Disease

Reference

causative
Dominant

Yes

(Sreedharan, et al., 2008)

Dominant

Yes

(Kwiatkowski, et al., 2009)

and

(Mackenzie, Rademakers, &

Recessive

Neumann, 2010)

Dominant

(Ticozzi, et al., 2011)

and
Recessive
EWSR1

Inconclusive

(Couthouis J. , et al., 2012)

ANG

Dominant

(Greenway, et al., 2004)
(Greenway, et al., 2006)

SETX

Dominant

Yes

(Chen, et al., 2004)

hnRNPa1

Dominant

Yes

(Kim, et al., 2013)

MATR3

Dominant

(Johnson, et al., 2014)

ARHGEF28

Unknown

(Droppelmann, et al., 2013)
(Ma, et al., 2014)

Proteinopathy C9orf72

Dominant

Yes

(Renton, et al., 2011)
(DeJesus-Hernandez,
Mackenzie, Boeve, & al.,
2011)

OPTN

Dominant

Yes

(Maruyama, et al., 2010)

Dominant

Yes

(Deng, et al., 2012)

Dominant

Yes

(Rosen, et al., 1993)

and
Recessive
UBQLN2
Enzymatic SOD1
activity

and
Recessive

Cytoskeletal NEFH

Dominant

(Al-Chalabi, et al., 1999)
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Dynamics PRPH
DCTN1

Sporadic

(Gros-Louis, et al., 2004)

Dominant

(Munch, et al., 2004)
(Vilariño-Güell, et al., 2009)

Others ALS3

Unknown

(Hand, et al., 2002)

ERBB4

Dominant

(Takahashi, et al., 2013)

ALS7

Dominant

Yes

(Sapp, et al., 2003)

Gene abbreviations: ANG = Angiogenin; ARHGEF28 = Rho Guanine Nucleotide
Exchange Factor; C9orf72 = Chromosome 9 Open Reading Frame 72; DCTN1 = Dynactin 1;
ERBB4 = erb-b2 receptor tyrosine kinase 4; EWSR1 = Ewing Sarcoma Breakpoint Region 1;
FUS/TLS = Fused in Sarcoma/Translocated in Liposarcoma; hnRNPa1 = Heterogeneous Nuclear
Ribonucleoprotein A1; MATR3 = Matrin 3; NFH = High Molecular Weight Neurofilament;
OPTN = Optineurin; PRPH = Peripherin; SETX = Senataxin; SOD1 = Superoxide Dismutase 1;
TAF15 = TATA-Binding Protein Associated Factor 2N; TARDBP = TAR DNA-Binding Protein
of 43 kDa; UBQLN2 = Ubiquilin 2.
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1.2.1 Protein homeostasis
Neuronal cytoplasmic inclusions (NCIs) identified in ALS post-mortem tissues are
predominantly skein-like inclusions or Lewy-body like hyaline inclusions that are ubiquitinated
(Haegawa, et al., 2008) (Robinson, et al., 2013). In fact, ubiquitinated inclusions are the most
abundant form of inclusions detected in ALS motor neurons, in which ubiquitin binds and marks
misfolded and abnormal proteins for proteasomal degradation. ALS motor neurons are unable to
activate the proper pathways for protein degradation, resulting in the accumulation of
ubiquitinated proteins in aggregates (Basso, et al., 2009) (Bendotti, et al., 2012). Researchers
have identified various ALS-associated proteins linked to loss of protein homeostasis in ALS and
they include SOD1, C9ORF72 and OPTN.
1.2.1.1 Cu/Zn Superoxide dismutase 1 (SOD1)
Cu/Zn Superoxide dismutase 1 (SOD1) is a 153 amino acid homodimer ubiquitously-expressed
protein composed of two subunits with a stabilizing zinc and a catalytic copper ion in each
subunit. SOD1 is an abundant cytoplasmic enzyme present in all cells in almost all organisms
and is a highly conserved protein (Lui, et al., 2004). The primary function of SOD1 is to remove
superoxide generated by the cells to reduce the generation of reactive oxygen species (Bendotti
& Carrì, 2004).
SOD1 was the first gene to be linked to ALS (Rosen et al., 1993). There are currently
over 150 SOD1 mutations associated with fALS, accounting for 15 - 20% of fALS cases and
approximately 3% of sALS cases (Anderson, 2006) (Ghasemi & Jr., 2018). Most mutations are
missense mutations present across the coding sequence resulting in an exchange of amino acids
without altering the size of the protein (Cleveland & Rothstein, 2001) (Andersen, et al., 2003)
(Lui, et al., 2004). The rest of the mutations associated with ALS are nonsense mutations
resulting in the alteration of the length of the final protein, silent mutations conserving both the
length and the sequence of the protein, and nonpathogenic intronic mutations found in ALS cases
and controls (Restagno, et al., 2005). In the case of many pathogenic SOD1 mutations, little to
no effect has been observed on their enzymatic activity which excludes a loss of function
mechanism. Indeed, the available evidence points to a gain of toxic function linked to the
mutated SOD1 that results in motor neuron degeneration (Gurney, et al., 1994). Of relevance to
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our understanding of ALS, neuropathological studies have demonstrated SOD1 immunoreactive
neuronal cytoplasmic inclusions in cortical and spinal cord tissue of ALS patients with and
without SOD1 mutations (Forsberg, et al., 2019).
In contrast, our group previously examined the expression of SOD1 using
immunohistochemistry in three variants of ALS: familial, sporadic and mtSOD1 cases compared
to healthy controls (Keller, et al., 2012). The results showed the specific expression of SOD1 in
diffuse cytoplasmic inclusions in motor neurons of mtSOD1 cases only, suggesting that the
mtSOD1-ALS variant possesses a unique pathological signature that distinguishes it from other
variants of ALS. Among the possible mechanisms, cf mtSOD1 toxicity, our lab demonstrated the
interaction of mtSOD1 with human NEFL mRNA and its effect on the RNA stability (Ge,
Strong, Laystra-Lantz, & Strong, 2005) (Volkening, Leyster-Lantz, Yang, Jaffee, & Strong,
2009). By destabilizing NEFL mRNA, the stoichiometry of NF expression is altered in a manner
that leads to the formation of NCIs (Ge, Leystra-Lantz, Wen, & Strong, 2003).
1.2.1.2 Chromosome 9 open reading frame 72 (C9orf72)
An autosomal dominant variant of ALS has been identified in association with genetic mutation
on chromosome 9q21 encoding C9orf72 protein (Vance, et al., 2006) (Renton, et al., 2011)
(DeJesus-Hernandez, Mackenzie, Boeve, & al., 2011). The number of hexanucleotide sequence
repeats in C9orf72 ranges from 0 to 22. In ALS patients, the mutation detected is a massive
intronic hexanucleotide repeat expansion (GGGGCC) (DeJesus-Hernandez, Mackenzie, Boeve,
& al., 2011) and the number of repeats ranges from 30 to several thousand (Renton, et al., 2011).
The pathological expansion of hexanucleotide repeats in C9orf72 is the most frequent
genetic mutation causing ALS and frontotemporal dementia (FTD) in European and North
American population, accounting for 11.7% of familial FTD cases and 23.5% of fALS cases
(DeJesus-Hernandez, Mackenzie, Boeve, & al., 2011). It was also determined as a genetic cause
in 5.1% of sporadic FTD patients and 5.9% of sporadic ALS patients (Blitterswijk, DeJesusHernandez, & Rademakers, 2012).
Previous findings related to non-coding repeat expansion disorders showed that by the
formation of RNA foci in the nucleus and/or cytoplasm, RNA-binding proteins are sequestered
which leads to the dysregulation of alternative mRNA splicing (Miller, et al., 2000) (Sofola, et
al., 2007) (White, et al., 2010). Initial reports of RNA foci in patients with C9orf72 repeat
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expansions demonstrated their presence in approximately 25% of the cells in the frontal cortex
and the spinal cord. Indeed, analyses of the brain tissue of patients with C9FTD/ALS showed the
presence of sense and antisense RNA foci C9orf72 positive (DeJesus-Hernandez, Mackenzie,
Boeve, & al., 2011). Previous findings showed that the most pathological feature of C9orf72 is
the presence of RNA-binding protein TDP-43 positive inclusions in neurons of ALS cases with
C9orf72 mutations (Davidson, et al., 2016).
Interestingly, despite their location in non-coding regions, C9orf72 repeat expansions are
capable of starting their own translation through a non-canonical mechanism known as repeatassociated non-ATG (RAN) translation (Zu, et al., 2011). This leads to the formation of neuronal
inclusions containing dipeptide repeat proteins (DRPs) generated through RAN translation
(Mori, et al., 2013).
As evidenced by the data from numerous studies on the role of C9orf72 repeat
expansions in ALS and other neurodegenerative diseases, three possible mechanisms seem to be
involved in the pathogenesis of C9orf72-associated ALS and these include a loss of function of
C9orf72 protein, the gain of toxic function caused by the sense and antisense C9orf72 repeat
expansions, or a direct toxicity of the DRPs (Balendra & Isaacs, 2018). Which of these proposed
mechanisms is the dominant one remains to be determined.
1.2.1.3 Optineurin (OPTN)
Optineurin is a highly conserved protein that is involved in several cellular processes, including
the inflammatory response, autophagy and vesicular transport. It is ubiquitously expressed in
many tissues including the eye, kidney, heart, liver and brain (Rezaie & Sarfarazi, 2005) (Rezaie,
Waitzman, Kaufman, & Sarfarazi, 2005).
OPTN is considered to be an ALS-associated gene for which greater than 20 mutations
have been described (Li, et al., 2015). The identified mutations in a Japanese cohort of familial
and sporadic ALS predicts that the recessive mutation causing ALS is a loss of function
mechanism on the one hand and on the other hand, the upregulation and distribution of mutated
OPTN causes a disruption in neuronal functions alongside the formation of inclusions in sporadic
ALS (Ying & Yue, 2016). OPTN has been found in pathological structures in ALS (Maruyama,
et al., 2010) where pathological skein-like inclusions immunoreactive for ubiquitin and TDP-43
are also immunoreactive for OPTN (Maruyama, et al., 2010) (Osawa, et al., 2011). A semi9

quantitative analysis performed on different variants of ALS spinal cord tissues in our lab
showed that while OPTN immunoreactive NCIs are not present in healthy controls, they are
observed in the spinal cord of a wide range of ALS variants including sALS, mtC9orf72-ALS,
fALS, mtFUS-ALS and mtTDP-43 ALS patients (Keller, et al., 2012).
While specific mutations of OPTN have been determined to cause ALS in various studies
(Maruyama, et al., 2010) (Fifita, et al., 2017), the specific role of OPTN in the pathogenesis of
ALS pathology remains unclear. In fact, dysfunctions in various cellular mechanisms have been
linked to the protein including endoplasmic reticulum stress (Vaibhava, et al., 2012), autophagy
(Bansal, et al., 2018) and neuroinflammation (Sako, et al., 2012). The mechanism by which
OPTN regulates neurodegeneration in ALS is however unknown.
1.2.2 Cytoskeletal dynamics
Cortical and spinal motor neurons are polarized cells with a soma, dendrites and extended axons
allowing them to participate in the directional flow of information from the central nervous
system to the rest of the body systems. (Lambrechts, Robberecht, & Carmeliet, 2007) (Rolls &
Jegla, 2015). To maintain its polarity and therefore function, the cytoskeletal organization of the
motor neurons is critical. The main components of the cytoskeleton consist of a dynamic and
complex network of protein filaments, including microtubules and intermediate filaments. The
involvement of neuronal intermediate filaments in ALS has been determined in
immunohistochemical studies identifying the presence of neurofilament subunits and peripherin
in which defects in their metabolism resulted in the loss and degeneration of upper and lower
motor neurons (Munoz, Green, Perl, & Selkoe, 1988) (Troost, Smith, Jong, & Swaab, 1992).
1.2.2.1 Intermediate filaments
Early studies of axonal transport identified three neuronal intermediate filament proteins of
different molecular size 200kDa, 160kDa and 68kDa (Hoffman & Lasek, 1975) that further
biochemical studies confirmed as the three subunits of the neurofilament (NF), the light (NFL),
the medium (NFM) and the heavy (NFH) weight neurofilament (Liem, Yen, Salomon, &
Shelanski, 1978). Together with the intermediate filament α-internexin, these make up for the
primary neuronal intermediate filaments of the CNS (Pachter & Liem, 1985). In the peripheral
nervous system (PNS), the fourth subunit constituting the NFs rather than internexin is
peripherin (Portier, de Néchaud, & Gros, 1983).
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In vivo studies on transgenic mice and in vitro studies in cells showed that in healthy
neurons, neurofilaments are generated by the stoichiometric heteropolymerization of the NF
subunits NFL and α-internexin/peripherin with NFM and/or NFH (Lee, Xu, Wong, & Cleveland,
1993) (Ching & Liem, 1993) (Yuan, et al., 2006) (Beaulieu, Robertson, & Julien, 1999). The
stoichiometric co-assembly of these subunits into a filamentous structure is responsible for the
axon caliber and cell integrity (Elder, et al., 1998).
Neurofilament accumulations are found in NCIs of both sALS and fALS and studies on
in vivo models show that the overexpression of neurofilament proteins leads to alterations in the
three subunits stoichiometry resulting in the disruption of axonal transport of NFs in motor
neurons (Al-Chalabi & Miller, 2003). To better understand the correlation between the
stoichiometric composition of the NFs and the ALS-related neuronopathy, the Julien group
developed transgenic mice models expressing the human NEFH gene (Côté, Collard, & Julien,
1993). The results showed that, even with a modest overexpression of NFH subunit, the mice
exhibited a progressive degeneration of their motor functions causing tremors and progressive
signs of weakness like those observed in ALS patients. These features were accompanied by the
presence of an abnormal accumulation of neurofilaments in the perikaryal and proximal axons of
motor neurons of the anterior horn, similar to the neuronal swellings found in the motor neurons
of ALS patients (Hirano, Donnenfeld, Sasaki, & Nakano, 1984).
Therefore, maintaining the NFs stoichiometry by controlling the expression levels of NF
subunits is critical since alterations in the stoichiometry result in the formation of NF aggregates.
1.2.3 RNA homeostasis
The discovery of alterations in the metabolism of RNA-binding proteins (RBPs) in ALS,
typically manifested as intracellular inclusions, provided a contemporary approach to the
development of in vivo and ex vivo models of the disease process. Subsequent studies have
supported the hypothesis that RNA dysmetabolism plays a critical role in the pathogenesis of
ALS including impacts on transcription, alternative splicing, microRNA biogenesis, mRNA
stability, mRNA compartmentalization and axonal transport of translationally quiescent mRNA
(Strong, 2010).
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1.2.3.1 TAR DNA-binding protein of 43kDa (TDP-43)
TDP-43 is a nucleic acid binding protein primarily localized in the nucleus with a small fraction
localized in the cytoplasm. It has two highly conserved domains, RNA-recognition domains 1
and 2 (RRM1 and RRM2), allowing the protein to bind to highly (UG)n enriched sequences
(Lukavsky, et al., 2013). Its amino-terminal and carboxy-terminal ends are mainly responsible
for protein-protein interactions involving TDP-43 (Budini, Baralle, & Buratti, 2014). In normal
conditions, TDP-43 can shuttle between the nucleus and cytoplasm, mediated by a nuclear
localization signal (NLS) located in the N-terminus region and the nuclear export signal (NES) in
RRM2. It is involved in numerous RNA processes including transcription, splicing, RNA
stability, transport, localization and stress granule (SG) formation (Buratti, 2015).
The observation of ubiquitin and TDP-43 immunoreactive neuronal cytoplasmic and glial
inclusions in the spinal cord tissue of ALS patients, consisting of hyperphosphorylated TDP-43
provided the first evidence supporting the potential role of altered RNA homeostasis in the
pathogenesis of ALS (Arai, et al., 2006). At the same time, Neumann et al (2006) observed
similar TDP-43 immunoreactive inclusions in both frontotemporal lobar degeneration (FTLD)
and ALS (Neumann, et al., 2006). Immunohistochemistry results from hippocampus, frontal and
temporal cortex of ALS patients showed that the pathologic TDP-43 protein is ubiquitinated,
hyperphosphorylated and cleaved resulting in the generation of toxic C-terminal fragments
(Neumann, et al., 2006).
An additional breakthrough in understanding ALS pathogenesis was the discovery of
dominant causative mutations on the encoding gene TARDBP in both fALS and sALS cases
(Sreedharan, et al., 2008). The identified TARDBP mutations include missense, truncations and
insertion/deletion, collectively accounting for about 5% of fALS cases (Buratti, 2015).
Under pathological conditions, TDP-43 accumulates in the cytoplasm in inclusions
accompanied by TDP-43 clearing from the nucleus; the latter being proposed to cause a loss of
the nuclear functions of TDP-43 (Ederle & Dormann, 2017). The formation of TDP-43
pathological inclusions is associated with extensive post-translational modifications including
ubiquitination, phosphorylation, formation of C-terminal fragments and acetylation, that
promotes the aggregation process and toxicity (Igaz, et al., 2009) (Buratti, 2018). The presence
of TDP-43 protein inclusions in brain and spinal cord tissue are a signature of ALS pathology.
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As previously demonstrated by our group, TDP-43 is an NEFL mRNA binding protein (Strong,
et al., 2007) alongside mutant and wild type SOD1 (Ge, Strong, Laystra-Lantz, & Strong, 2005)
and rho guanine nucleotide exchange factor (RGNEF) (Volkening, Leystra-Lantz, & Strong,
2010) (Droppelmann, Keller, Campos-Melo, Volkening, & Strong, 2013). In vitro data show that
the presence of a unique UG motif at the 3‘UTR of NEFL mRNA allows the RRM1 and RRM2
domains of TDP-43 to specifically interact with this mRNA (Volkening, Leyster-Lantz, Yang,
Jaffee, & Strong, 2009). In ALS, TDP-43 co-localizes with an array of RNA granules including
transport granules (Staufen-1 immunoreactive), stress granules (TIA 1 immunoreactive),
processing granules (XRN1 immunoreactive). This suggest that TDP-43 may be sequestrated in
RNA granules in ALS, thus impacting their role in modulating RNA stability.
TDP-43 has also been determined to have many splicing targets including FUS/TLS and
its own 3’ untranslated region (UTR) (Polymenidou, et al., 2011), as well as playing a role in
microRNA metabolism (Buratti, et al., 2010).
1.2.3.2 Fused in sarcoma/translocated in liposarcoma (FUS/TLS)
FUS/TLS (commonly abbreviated as FUS) is a DNA/RNA-binding protein mainly localized in
the nucleus where it participates in various cellular processes including transcription and splicing
(Ling, Polymenidou, & Cleveland, 2013). It is an hnRNP protein and belongs to the FET protein
family that includes TAF15 and EWS (Morohoshi, Arai, Takahashi, Tanigami, & Ohki, 1996).
The protein structure of FUS consists of an amino-terminal transcription activation domain - the
Gln-Gly-Ser-Tyr (QGSY)-rich region, a highly conserved domain RNA recognition motif
(RRM) and three Arg-Gly-Gly (RGG)-repeat regions, a zinc finger motif and a highly conserved
carboxy-terminal region implicated in RNA binding (Iko, et al., 2004). FUS is heavily involved
in transcription regulation, facilitated by the role of the amino-terminal region in FUS
dimerization and binding to chromatin. Moreover, FUS is responsible for the phosphorylation of
RNA polymerase II (RNA-polII) during transcription and therefore in regulating its activity.
About 5% of fALS cases occur in association with mutations in the FUS gene. The most
abundant missense/deletion mutations identified in ALS occur in the carboxy-terminal region
containing the nuclear localization signal where they have been shown to lead to an abnormal
distribution of mutant FUS in the cytoplasm (Kwiatkowski, et al., 2009). In the presence of FUS
ALS-associated mutations, the transcription activity of RNA-polII and FUS leads to a down13

regulation of the RNA species (Yang, Gal, Chen, & Zhu, 2014) (Masuda, et al., 2015). FUS is
among the proteins identified in pathological NCIs in ALS motor neurons in both mutant FUSlinked fALS and sALS (Deng, Gao, & Jankovic, 2014).
Among the proposed mechanisms by which FUS causes the disease is a toxic gain of
function. In fact, a homozygous FUS knockout mouse model demonstrated that the dysfunction
of FUS led to a behavioral phenotype distinct from ALS suggesting that a loss of function alone
is not enough for FUS to trigger ALS pathology (Kino, et al., 2015). On the other hand, results
from transgenic mice overexpressing human FUS show an increase in the expression of
cytoplasmic FUS present in globular and skein-like FUS-positive inclusions. Moreover, the
homozygous animals developed an aggressive phenotype with pathological features like those
seen in ALS patients (Mitchell, et al., 2013).
1.2.3.3 TATA box-binding protein-associated factor 15 (TAF15) and Ewing sarcoma b1
(EWS).............................
TATA box-binding protein (TBP)- associated factor 15 and Ewing sarcoma b1 (EWS) are RBPs
that belong to the FET family of heterogenous nuclear ribonucleoparticle proteins (hnRNPs).
They are predominantly expressed in the nucleus. Both TAF15 and EWS are capable of shuttling
from the nucleus to the cytoplasm and participate in transcription and alternative splicing
(Morohoshi, Arai, Takahashi, Tanigami, & Ohki, 1996) (Couthouis J. , Hart, Shorter, & al,
2011). TAF15 has been shown to have unique intronic binding patterns in which it preferably
binds to GGUA motifs in RNA (Kapeli, et al., 2016). However, TAF15 affects only a small
number of alternative splicing events. It plays a more significant role in the stability of
significant mRNA populations (Kapeli, et al., 2016) where TAF15 has been reported to recruit
RNA polymerase II to sites of active transcription in complex with transcription factor II D
(TFIID) (Bertolotti, Lutz, Heard, Chambon, & Tora, 1996) (Kwon, et al., 2013). In sALS
patients, mislocalization of TAF15 to the cytoplasm in motor neurons is evident (Couthouis J. ,
Hart, Shorter, & al, 2011). Because of the presence of prion-like domains and its low-complexity
feature it is prone to aggregation (Kwon, et al., 2013).
Of note, EWS mutations have only been detected in sALS patients, including three
missense variants which were determined to be involved in the mislocalization of EWS in motor
neurons (Couthouis J. , Hart, Shorter, & al, 2011) (Couthouis J. , et al., 2012). In vivo analysis of
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the effects of EWS in transgenic flies expressing human EWS is associated with degeneration in
the eye of the fly, a shortened life span and progressive loss of motor functions (Couthouis J. , et
al., 2012). While these observations provided a new insight regarding EWS properties in ALS,
the role of the protein in the pathogenesis of ALS awaits further investigation.
1.2.3.4 Rho Guanine Nucleotide Exchange Factor (RGNEF)
RGNEF is a 190 kDa RNA-binding protein, part of the diffuse B-cell lymphoma (Dbl) family of
guanine exchange factors (GEFs). Its murine homologue was first cloned from the mouse brain
cDNA library as p190rhoGEF (murine isoform). The activation of Rho GTPases leads to the
activation of various cellular responses including cell adhesion, motility, transcription activation
and cell cycle progression (Mackay & Hall, 1998). p190RhoGEF is a specific activator of RhoA
that can interact with microtubules through its carboxy-terminal region (van Horck, Ahmadian,
Haeusler, Moolenaar, & Kranenburg, 2001). In addition to its microtubule domain located within
the carboxy-terminal end, RGNEF also has a focal adhesion kinase (FAK) domain. Located in a
coil-coiled domain, it facilitates the direct interaction with FAK (Zhai, et al., 2003); which is in
turn involved in cell adhesion to the extracellular matrix (ECM) (Kornberg, Earp, Parsons,
Schaller, & Juliano, 1992). However, a dysregulation of these cell-matrix contact sites leads to a
dysregulation in cell migration resulting in cancer cell growth and proliferation (Guan &
Shalloway, 1992).
RGNEF has five important domains: a leucine-rich domain (LeuR) and a cysteine-rich
Zn-binding domain in the amino terminal half of the protein; a Dbl homology domain (DH), a
Pleckstrin homology domain (PH) and an RNA-binding domain in the carboxy-half of the
protein (Cañete-Soler, Wu, Zhai, Shamim, & Schlaepfer, 2001) (Droppelmann, Campos-Melo,
Volkening, & Strong, 2014) (Cheung, et al., 2017).
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Figure 1. Structure of full length RGNEF. RGNEF is 1731 amino acid protein with eight
putative domains: a leucine-rich domain (LeuR), an Ankyrin repeat domain overlapping with
LeuR and a cysteine-rich Zn-binding domain in the amino terminal half of the protein ; a Dbl
homology domain (DH), a Pleckstrin homology domain (PH), an RNA-binding domain, a FAK
binding domain overlapping with the RBD and a microtubule binding domain overlapping with
the RBD and extending to the amino acid 1731 in the carboxy-half of the protein (Droppelmann,
Campos-Melo, Volkening, & Strong, 2014).
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RGNEF is the only known RNA-binding protein to be also identified as a GEF protein
with the capacity to activate RhoA. Our lab and others have observed mutations in the gene
encoding RGNEF, ARHGEF28, in both sALS and fALS (Droppelmann, et al., 2013) (Song, et
al., 2020). These mutations are predicted to generate either a frameshift mutation or a splicing
mutation resulting in a truncated RGNEF of 319 or 259 amino acids (Fig. 2). The single
nucleotide deletion detected results in the generation of a massively smaller protein compared to
the normal 1731 amino acid RGNEF (Droppelmann, et al., 2013).
Schlaepfer and colleagues have demonstrated the critical role of RGNEF in the spread of
colon carcinoma and fibroblast cell motility (Miller, Lawson, Chen, Ssang-Taek, & Schlaepfer,
2012). Their results suggest that RGNEF has a scaffolding role in the localization and activation
of FAK (Miller, et al., 2013) in addition to its GEF activity regulating RhoA in control of cell
migration (Miller, Lawson, Chen, Ssang-Taek, & Schlaepfer, 2012).
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Figure 2. Frameshift mutation in RGNEF in a case of fALS. (A) Sequence profile showing
the mutation and the single nucleotide deletion at the exon-intron 6 boundary found in ALS-5.
These mutations are predicted to generate a frameshift mutation with premature truncation,
namely K280M>fs40X (B) or a splicing mutation at the exon 6/intron 6 splice junction, namely
intron 6, >1 delG (GT>TT) (C), which would cause exon 6 skipping. (D) Predicted protein
products of frameshift mutation compared with full length RGNEF (Droppelmann, et al., 2013).
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Under normal physiological conditions, RGNEF is mainly localized in the cytoplasm
with moderate nuclear levels of expression (Droppelmann, Keller, Campos-Melo, Volkening, &
Strong, 2013). RGNEF forms pathological NCIs in motor neurons in both sporadic and familial
ALS forms (Keller, et al., 2012) (Droppelmann, Keller, Campos-Melo, Volkening, & Strong,
2013). Further RGNEF co-localizes with the RNA-binding proteins TDP-43 and FUS within
motor neuron NCIs in ALS. We have also observed an interaction between full length RGNEF
and TDP-43, further supporting the pathogenic role of RGNEF in ALS (Keller, et al., 2012).
In a murine model of neuronal stress (proximal sciatic axotomy), RGNEF is significantly
upregulated, suggesting it acts as stress and survival factor (Cheung, et al., 2017). This was
confirmed in vitro in HEK 293T cells in which RGNEF increased cell survival following
exposure to oxidative or osmotic stress (Cheung, et al., 2017). In the same study, we observed
the colocalization of RGNEF with Staufen-1 in SGs. The murine homologue of RGNEF,
p190RhoGEF has been observed to interact with a destabilizing region in the 3’ untranslated
region (UTR) domain of murine NEFL mRNA in order to stabilize its transcript (Cañete-Soler,
Wu, Zhai, Shamim, & Schlaepfer, 2001). Further studies looking into the aggregation process of
NFL protein, showed that in an established cellular model, Neuro2a cells, p190RhoGEF colocalized with NFL protein aggregates and not with NFL subunit. Additionally, NFL protein
aggregation was associated with the co-aggregation of p190RhoGEF in motor neurons in a
transgenic mouse model of motor neuron disease (Lin, Zhai, & Schlaepfer, 2005). In our lab, we
have shown that the RNA-binding domain of RGNEF, interacts with NEFL mRNA (Volkening,
Leystra-Lantz, & Strong, 2010). However, in contrast to the stabilizing effect of p190RhoGEF
on murine NEFL mRNA, RGNEF destabilizes human NEFL mRNA via its 3’UTR
(Droppelmann et al. 2013)
Recently, we have examined the formation of micronuclei in ALS in response to stress
(Droppelmann, Campos-Melo, Moszczynski, Amzil, & Strong, 2019). Despite the limited studies
on micronuclei in neurodegeneration and ALS in particular, it has previously been noted that
these structures are present in peripheral blood lymphocytes of Alzheimer’s disease (AD) and
Parkinson’s disease (PD) patients (Migliore, Cappodè, Fenech, & Thomas, 2011). Using lactate
stress-induced HEK 293T cells, we observed the formation of micronuclei, containing both TDP43 and LeuR, the latter being a protein containing leucine repeats within the first 242 amino
acids of RGNEF. In addition, we have observed that TDP-43 and LeuR co-immunoprecipitate in
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a high molecular weight complex. These observations suggest a role for the LeuR in the coaggregation of RGNEF and TDP-43 (Droppelmann, Campos-Melo, Moszczynski, Amzil, &
Strong, 2019). The presence of micronuclei-like structures was also confirmed in the
hippocampus and spinal cord of ALS patients with TDP-43 pathology.

1.3 Leucine-Rich Repeat protein family
Leucine Rich Repeats (LRR) are present in many proteins in humans and are one of the most
conserved domain repeats across species (Matsushima, et al., 2007). Early studies looking into
the structure of the porcine ribonuclease inhibitor enabled researchers to model other LRR
proteins and their ligand complexes (Kobe & Deisenhofer, 1993). LRR are generally composed
of 20 to 29 residues repeat in tandem containing a conserved 11-residue segment with a
consensus sequence LxxLxLxxNxL (L= leucine; x= any amino acid; N= asparagine, cysteine,
threonine or serine). The repeated tandems are grouped into highly conserved segments (HCS)
and variable segments (VS) and are known to form a continuous superhelix (Kobe & Kajava,
2000) (Table 2). They have been shown to play a critical role in protein-protein interaction and
other cellular processes such as neural development and modulation of different growth factor
pathways (Ghiglione, et al., 1999).
Protein-protein interactions are involved in most biological processes of a cell in both
normal and pathological conditions. Given the role of protein misfolding, aggregation and
degradation in neurodegenerative disease, researchers are using interaction proteomics in order
to establish the interacting partners of established neurodegenerative disorders-associated
proteins, and by identifying binding partners, determine their potential functions (Hosp, et al.,
2015).
The amino-terminal region of RGNEF contains an atypical leucine rich motif located
between the amino acids 97 and 206 (Table 2). While the structure of full length RGNEF is still
not known, a software analysis of the LeuR242 sequence predicts the presence of alpha helices
(Fig. 3) comparable to the structure of other leucine rich repeats in the literature (Dolan, et al.,
2007).
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Table 2. Identified subfamilies of Leucine Rich Repeat sequences. LRR conserved consensus
sequences by Kobe and Kajava (Kobe & Deisenhofer, 1993) (Kobe & Kajava, 2000) and an
identified atypical LeuR sequence of RGNEF.
Subfamily

Conserved consensus sequence

Ribonuclease inhibitor LxxLxLxxN/CxL
SD22-like

LxxLxLxxNxL

Cys-containing

LxxLxLxxcx-x

Bacterial

LxxLxVxxNxL

Plant specific

LxxLxLxxNxL

Typical

LxxLxLxxNxL

TpLRR

LxxIxLx-xxLx

Atypical LeuR

LxxLLxxxxNxL

Abbreviations:SD22= G-type lectin S-receptor-like serine/threonine-protein kinase; Cys=
cysteine; TpLRR= T. pallidum leucine-rich repeat; L= leucine; x= any residue; N= asparagine; = possible insertion site.
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Figure 3. Prediction of secondary structure of the LeuR domain of RGNEF. The model was
created using I-Tasser (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) based on the sequence
of LeuR242 amino acids 1 to 242. The modelling shows the presence of nine α-helices ranging
from amino acids 95 through 220 in the middle of the leucine-rich domain of RGNEF. Pink
indicates α-helix structure; yellow indicates β-unit structure.
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Our group has previously demonstrated that when the full-length protein was truncated
into various domains, the Leucine-Rich (LeuR) region proved to be critical for its cytoprotective
effect under osmotic stress conditions (Cheung, et al., 2017). In addition, under stress, RGNEF
co-localizes with Staufen-1 positive granules. Moreover, in unpublished observations, we have
found that LeuR confers a protective effect in vivo against the toxicity of TDP-43 in a double
transgenic LeuR;TDP-43 drosophila melanogaster model, improving the flies’ lifespan, motor
functions and the eye degeneration observed in single transgenic flies TDP-43 (Droppelmann,
unpublished results).

1.4 Rationale and hypothesis
ALS is a progressive, adult-onset disease characterized by the degeneration of motor neurons.
The presence of neuronal cytoplasmic inclusions (NCIs) composed of RNA-binding proteins,
neurofilaments and other proteins, is considered to be the disease’s neuropathological hallmark.
Amongst ALS-associated proteins, RGNEF has been identified as a novel protein involved in the
pathogenesis of ALS as it has been observed to co-aggregate with RNA-binding proteins TDP43 and FUS within motor neuron NCIs in ALS. RGNEF is a 190 kDa RNA-binding protein with
five important domains including a leucine-rich region (LeuR) domain in the amino terminal half
of the protein. Given previous data demonstrating the interaction of RGNEF and the LeuR
domain of RGNEF with TDP-43 and considering that RGNEF has been observed to regulate the
levels of NEFL mRNA and NFL protein in vitro, I hypothesize that there is a functional and
biochemical interplay between RGNEF and TDP-43 in which RGNEF can regulate the
levels of TDP-43 and where the interaction between these two proteins is regulated by a
minimal domain contained within the LeuR region of RGNEF.

1.5 Significance and impact of the research
This work will help elucidate the role of RGNEF in regulating the ALS-related protein TDP-43
and how a small domain contained in the LeuR region of RGNEF is critical for the physical
interaction between RGNEF and TDP-43. Since the fly model used in this study shows a
protective effect of LeuR over the toxic phenotype induced by TDP-43 overexpression, the data
generated from immunostainings of brain and eye tissue from the flies will help us understand
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how aggregates containing LeuR and TDP-43 could be a possible mechanism of protection
against TDP-43 toxicity. By defining the role of the minimal domain of interaction between two
ALS-associated RBPs, RGNEF and TDP-43, we can get a step further into identifying a potential
therapeutic target in ALS.
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Chapter 2
2.1 Specific aims
2.1.1 Aim 1: To determine the minimal domain of interaction between LeuR242 and TDP43...............
The first aim was to determine the minimal domain of interaction between the LeuR242 region
(Fig. 4) and TDP-43. The predictive structure of full length RGNEF suggests the presence of an
atypical LeuR motif in the amino-terminal region of the protein. Given the role of the LeucineRich repeat proteins in protein-protein interaction, I hypothesized that within LeuR242, a smaller
fragment is required for the interaction with TDP-43. Previous results from a crosslink
immunoprecipitation showed the presence of an interaction between LeuR242 and TDP-43 in a
high molecular weight complex (Droppelmann, Campos-Melo, Moszczynski, Amzil, & Strong,
2019). Since the LeuR242 construct generated in our lab contains the leucine-rich motif, from
amino acids 97 to 206, and sequences of RGNEF on both its amino and carboxy-terminal ends,
we generated various constructs of LeuR242 in order to determine the minimal domain critical for
the protein-protein interaction observed.
2.1.2 Aim 2: To study the regulation of ALS-related protein TDP-43 by full length RGNEF
and different RGNEF constructs (ΔLeuR and ΔCOOH) designed to elucidate the role
of LeuR242
The second aim was to study the regulation of ALS-related proteins by full length RGNEF and a
variety of RGNEF constructs (ΔLeuR and ΔRBD) designed to elucidate the role of RGNEF.
Given that RGNEF is an RNA-binding protein and given the role of these proteins on ALSrelated proteins, such as TDP-43, I hypothesized that the amino-terminal region of RGNEF
contains a domain responsible for the regulatory effect observed over TDP-43 in vitro.
Considering that RGNEF has been observed to regulate the levels of NEFL mRNA and NFL
protein, I investigated the regulatory effect of RGNEF over the mRNA stability and protein
levels of TDP-43.
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2.1.3 Aim 3: To determine the interaction between TDP-43 and LeuR242 in vivo in a
drosophila melanogaster model of TDP-43 toxicity.
The third aim was to determine how the LeuR242 region modifies TDP-43 pathology in vivo.
Preliminary experiments conducted in our lab have demonstrated that both RGNEF and LeuR242
are critical modulators of the toxicity of wild-type TDP-43 drosophila melanogaster models with
a significant protective effect on both survival and motor functions. To better understand the
protective role of the LeuR242 region against the TDP-43 toxicity in the flies, I analyzed the
pathology of TDP-43 toxicity in the absence or presence of LeuR242 using IHC on the brain and
eye tissue of Elav-TDP-43 flies and Elav-LeuR242;TDP-43 flies.
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Figure 4. Schematic showing the LeuR region flag-tagged constructs used to study the
minimal domain of interaction with TDP-43. flag-LeuR242: previously characterized in the
interacting complex with TDP-43 and the LeuR region flag-tagged constructs used to study the
minimal domain of interaction with TDP-43; flag-LeuR110: containing only the LRR (amino
acids 97-206), flag-ANK: containing only the ANK repeat, including a small fragment of the Cterminal LRR (amino acids 162-229).
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2.2 Methods
2.2.1 Constructs elaboration
The constructs, LeuR110 and ANK domains, were generated by PCR amplification using Phusion
polymerase (Invitrogen, ThermoFisher Scientific) and primers specifically designed for each
construct (Table 3). All the constructs created contain a flag-tag sequence on their aminoterminal region, which allows the detection of the proteins expressed using an anti-flag antibody.
The PCR products used as insert were run on a 1% agarose gel at 90V for 60 minutes, purified
by gel extraction using a NuceloSpin Gel Extraction Kit (Macharey-Nagel Inc) and quantified
using a Nanodrop spectrophotometer (ThermoFisher Scientific). Each fragment insert was then
inserted into a pcDNA3.0 vector using the restriction enzymes KpnI and XhoI, after a 15 minutes
digestion at 37°C (Anza system, Invitrogen, ThermoFisher Scientific). The digested plasmids
and inserts were then ligated overnight at room temperature using T4 DNA ligase (Promega) at
3:1 molar ratio of insert:vector, and transformed afterwards using chemically competent cells
DH5α E.Coli per manufacturer’s protocol (Invitrogen, ThermoFisher Scientific). The
transformation was then plated onto a selective agar plate containing 100μg/ml ampicillin and
incubated overnight at 37°C. The obtained colonies were picked from the plate and grown in LB
broth containing 100μg/ml ampicillin overnight at 37°C with shaking at 225rpm. The next day,
DNA plasmids of each construct were obtained using PureLink Quick Plasmid Miniprep Kit per
manufacturer’s protocol (Invitrogen, ThermoFisher Scientific). The purified plasmids were first
screened through a 15minute enzymatic digestion at 37°C using Anza KpnI and XhoI, following
which they were run on a 1% agarose gel for 60 minutes at 90V and compared to a control
plasmid. 1Kb Plus molecular ruler (Bio-Rad) was used to determine the size of the plasmids on
the agarose gel. Afterwards, the plasmids observed at the expected size were sent for sequencing
(DNA Sequencing Facility - Robarts Research Institute) for confirmation before transiently
transfecting HEK 293T cells.
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Table 3. Primers used in PCR amplification to generate different constructs of LeuR
Forward or
Name

Reverse

DNA sequence (5’ - 3’)

primer
pcDNA3.0_flag-LeuR110

Forward

GTAGGTACCCACCATGGACTACAAGGACGAC
GATGACAAGCTGGCTCGTCTGCTGGTGAC

pcDNA3.0_ Leur110

Reverse

ACACTCGAGTTATAAAGCTAAGTCTAATGGT
GTGGCAC

pcDNA3.0_flag-ANK

Forward

GTAGGTACCCACCATGGACTACAAGGACGAC
GATGACAAGCACAGAGAATCTCTTCTACAC

pcDNA3.0_ ANK

Reverse

ACACTCGAGTTAGAAGCTTGGGGACCATCTG
CCCTGAA

*Restriction site sequences are underlined: KpnI = GGTACC; XhoI = CTCGAG

29

2.2.2 Cell culture
HEK 293T cells were used for all in vitro experiments because of their amenability to
transfection, their neuronal-like properties (Shaw, Morse, Arabat, & Graham, 2002) and their
endogenous expression of TDP-43. They were maintained in Dulbecco’s modified eagle’s
medium (Gibco, ThermoFisher Scientific) supplemented with 10% fetal bovine serum and kept
in a water-jacketed incubator at 37°C, 5%CO2 (ThermoFisher Scientific).
2.2.3 Transfections
For the in vitro experiments in aim 1 looking to determine the minimal domain of interaction of
LeuR with TDP-43, the cells were transiently transfected with flag-tagged plasmid constructs of
LeuR inserted in the pcDNA3.0 backbone vector or TDP-43 plasmid inserted in a
pcDNA3.1(+)/myc-His, each validated through sequencing (DNA Sequencing Facility - Robarts
Research Institute) and purified using the PureLink Midiprep kit according the manufacturer’s
protocol (Invitrogen, ThermoFisher Scientific). For the crosslink experiments of aim 1, the cells
were seeded in 10cm dishes at 1,000,000 cells/dish and the transient transfections was performed
using lipofectamine 2000 per the manufacturer’s protocol (ThermoFisher Scientific). The cells
were left to grow for 48h to attain a 70% confluency before transfection. Cells were transfected
with 15μg of DNA at a 2.5μL lipofectamine 2000 per 1μg DNA ratio and per manufacturer’s
protocol, cells were incubated with the complex lipofectamine 2000 -DNA in OPTIMEM media
(Invitrogen, ThermoFisher Scientific) for 3h. Afterwards, the cells were incubated in DMEM
complete media for 36h for recovery before protein lysis.
For the in vitro experiments in aim 2 looking to study the regulation of endogenous TDP-43,
HEK 293T cells were transiently transfected with RGNEF constructs previously generated in our
lab by C. Droppelmann (Cheung, et al., 2017). The following constructs, inserted in a
pcDNA3.1(+)/myc-His backbone vector, were used: full length RGNEF, RGNEF-ΔLeuR; and
RGNEF-ΔCOOH (Fig. 5). HEK 293T cells were seeded in 6-well plates (200,000 cells per well)
or 96-well plates (9,000 cells per well) and left to grow for 48 hours and 24 hours, respectively,
until they reach 70% confluency. Afterwards, cells were transfected using lipofectamine 2000
with 2.5μg of plasmid DNA in 6-well plates or 120ng of plasmid DNA in 96-well plates, at a
2.5μL lipofectamine per 1μg DNA ratio and per manufacturer’s protocol (Invitrogen,
ThermoFisher Scientific). Figure 6 illustrates the steps followed for each transfection.
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(A)

(B)

Figure 5. RGNEF constructs used to study the effect of its putative regions on the
endogenous expression of TDP-43 in vitro. (A) Aligned protein sequences of RGNEF
constructs full length RGNEF, RΔLeuR and RΔCOOH: --- indicates deleted amino acids in
RΔLeuR and RΔCOOH; green indicated the leucine rich domain; yellow indicates the cysteine31

rich Zn-binding domain; red indicates the Dbl homology domain (DH); blue indicates the
Pleckstrin homology domain (PH) and orange indicates the RNA-binding domain. (B) Scheme
of the RGNEF constructs used in transiently transfected HEK 293T cells to determine the
regions of RGNEF involved in the regulation of endogenous TDP-43.
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Transient transfection of HEK293T cells in normal conditions

Seed 200000 cells in 6 well plates and incubate 48h
at 37°C before transfection.

Seed 9000 cells in 96 well plates and incubate 24h
at 37°C before transfection.

Transfect cells with pcDNA3.1(+)/myc-His or
RGNEF constructs using the lipofectamine 2000.

Co-transfect cells with a renillaluciferase coding
sequence tagged to exogenous RGNEF and a
fireflyluciferase coding sequence tagged to TDP43 3’UTR or FUS 3’UTR using the lipofectamine
2000.

Lyse the cells 36-48h post transfection for protein
or RNA extraction for TDP-43 protein and mRNA
quantification, using western blot analysis and an
RT-PCR respectively.

Treat the cells 24h post-transfection and proceed to
the readings in Promega luminometer to measure
the luciferase activity of TDP-43 3’UTR in the
presence of exogenous RGNEF constructs.

Figure 6. Flow chart describing the transfection conditions in HEK 293T cells used to study
the regulation of TDP-43.
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2.2.4 Dual-luciferase reporter assay
To determine the role of RGNEF in the regulation of TARDP 3’UTR mRNA, a dual-luciferase
reporter assay was used on transiently co-transfected HEK 293T cells. The reporter plasmids,
previously generated in our lab by D. Campos-Melo, were constructed by inserting TARDBP
mRNA 3’UTR, or FUS mRNA 3’UTR in the pmirGLO vector (Promega) downstream of the
firefly luciferase gene. HEK 293T cells were co-transfected with 2.83fmol of RGNEF-myc or
pcDNA3.1 and 3.47fmol of pmirGLO-TARDBP 3’UTR; pmirGLO-FUS 3’UTR or pmirGLO
using lipofectamine 2000 (Invitrogen, ThermoFisher Scientific) per the manufacturer’s
instructions. The total amount of DNA transfected was maintained at 120ng per well by adding
an empty vector. Each condition was replicated in six wells and the mean luciferase activity was
used. The experiment was performed in triplicate.
24 hours post-transfection, cells were treated with a luciferase assay buffer (DualLuciferase Reporter Assay, Promega) and the firefly luciferase activity was measured using a
Luminometer (Turner Biosystems Luminometer, Promega) according to the manufacturer’s
protocol, following which the cells were treated with Stop & Glo reagent (Dual-Luciferase
Reporter Assay, Promega) and the Renilla luciferase activity was measured using a Luminometer
(Turner Biosystems Luminometer, Promega) according to the manufacturer’s protocol. Using the
normalization protocol previously reported from our lab (Campos-Melo, Droppelmann,
Volkening, & Strong, 2014), the measured firefly luciferase activity was normalized to measured
Renilla luciferase activity to account for the variations from transfection efficiency. The
luciferase activity from RGNEF over TARDBP 3’UTR or FUS 3’UTR was normalized against
the luciferase activity from RGNEF over mRNA without 3’UTR to determine the specific effect
of RGNEF on the luciferase activity of TARDBP 3’UTR and FUS 3’UTR.
2.2.5 Protein lysates
Protein lysates from HEK 293T transfected cells were obtained after lysing cells on ice using the
following lysis buffer: phosphate-buffered saline (PBS) pH 7.2 with 1% Nonidet P-40(NP-40)
and cOmplete protease inhibitor cocktail (Roche). After the cells were washed with PBS pH 7.2,
to each well and 10cm dish, 200μl and 1000μl of lysis buffer were added respectively and
scraped using a cell scraper. The lysed cells were then sonicated to homogenize (Sonifier Cell
Disruptor Vibracell, Sonics and Material Inc.), centrifuged at 10,000g, 4°C for 10 minutes to
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pellet cell debris and the supernatant with the proteins was extracted and stored at -20°C. The
quantification of the proteins in lysates were quantified using the Promega protein assay
according to the manufacturer’s protocol and the colorimetric analyses were measured using a
Nanodrop (ThermoFisher Scientific) reading at 600nm.
2.2.6 Crosslinking experiment
To determine the minimal domain of interaction between LeuR242 and TDP-43, the chemical
crosslinker dithiobis(sulfosuccinimidylpropionate) (DTSSP) was used in the presence of protein
lysates from HEK 293T transfected cells. A total of 500μg protein was used for the crosslinking,
combining 250μg of protein lysate from TDP-43-myc HEK 293T transiently transfected cells
and 250μg of protein lysate from flag-LeuR110 or flag-ANK HEK 293T transiently transfected
cells. The lysates were incubated at room temperature for 15 minutes before adding 10mM of
DTSSP for a final concentration of 1.2mM in a final volume of 500μl. The mixture was
incubated at room temperature for 30 minutes and the crosslinking reaction was stopped
afterward by adding 25μl of 1M Tris pH 7.5 for a final concentration of 50mM.
2.2.7 Immunoprecipitation
Immunoprecipitation was performed after the crosslinking using the Dynabeads Protein G IP Kit
(Invitrogen, ThermoFisher Scientific). IP experiments were performed by incubating 50μl of
protein G beads with 2μg of IP antibodies (Table 3) for 15 minutes on a rotator (Tube Revolver,
ThermoFisher Scientific) at room temperature. Afterwards, the antibody-conjugated beads were
washed and incubated with 500μg of previously crosslinked protein lysates for 15 minutes on a
rotator (Tube Revolver, ThermoFisher Scientific) at room temperature. The magnetic beadsantigen-antibody complex were then washed according to the manufacturer’s protocol
(Dynabeads Protein G IP Kit, ThermoFisher Scientific), eluted in PBS pH 7.2 and loading buffer
(0.32M Tris-HCl, 10% SDS, 50% glycerol, bromophenol blue). At this step, two different
elution conditions were used: non-reducing conditions to detect the complex of interacting
proteins and reducing conditions to detect the proteins after the complex was cleaved at the disulfide bond of DTSSP. In the case of non-reducing conditions, the beads were eluted in PBS
with 5X loading buffer, while in reducing conditions the beads were eluted in PBS with 5X
loading buffer and 0.68M β-mercaptoethanol. Samples were then heated at 94°C for 4 minutes
and placed on a magnet to separate the beads-antigen-antibody complex.
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2.2.8 Western blots
To complete the crosslink IP in aim 1, the supernatant containing the antigen-antibody complex
was loaded onto a gradient sodium dodecyl(lauryl) sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (4-20% Mini-PROTEAN TGX precast protein gels, Bio-Rad). To study the
regulation of endogenous TDP-43 in the presence of various constructs of RGNEF, a total of
15μg of protein lysate in lysis buffer mixed with 5X loading buffer and 0.68M βmercaptoethanol was loaded onto a 10% SDS-PAGE gel.
The gels were run on a constant of 100V for approximately 90 minutes, until the loading
dye reached the bottom edge of the gel in a running buffer containing 50mM TRIS base, 200mM
glycine, 2mM glycine in deionized water. Afterwards, the gels were transferred
electrophoretically to a nitrocellulose membrane at a constant 300mA for 90 minutes. To ensure
the transfer was successful, the nitrocellulose membranes were incubated with Ponceau-S red
solution (0.1%(w/v) Ponceau S in 5%(v/v) acetic acid) for a few minutes after the transfer. Once
confirmed, they were submerged in blotto solution (50mM TRIS base, 100mM NaCl, 1%
Tween-20 pH 7.2), at 4°C overnight. The nitrocellulose membranes were first blocked using
blocking solution (5% fat-free milk in blotto) for 60 minutes at room temperature on an orbital
shaker (ThermoFisher Scientific), then primary antibodies were diluted in blocking solution
afterwards, added to the membranes and incubated for 60 minutes at room temperature on an
orbital shaker (ThermoFisher Scientific). Afterwards, the nitrocellulose membranes were washed
three time in blocking solution 5 minutes each and then incubated with secondary antibodies
diluted in blocking solution. The list and quantities of antibodies used are listed in Table 4.
After secondary antibody incubation, the membranes were washed with blotto for 10 minutes
each at room temperature on an orbital shaker (ThermoFisher Scientific). After the final wash,
they were incubated in PBS pH 7.2 for 5 minutes at room temperature, and in Western Lightning
ECL reagents (PerkinElmer) for 3 minutes at room temperature in order to generate a
chemiluminescence signal. The signal was detected using ChemiDoc XRS+ system and
visualized using Image Lab software (Bio-Rad).
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Table 4. Antibodies used for western blot experiments
Primary

Species

Dilution Manufacturer Secondary antibody

Mouse

1:2500

antibody
Anti-myc

Cederlane

Goat α-mouse, linked to
horseradish peroxidase (titre:
1:3000) (Bio-Rad)

Anti-TDP-43

Rabbit

1:5000

ProteinTech

Goat α-rabbit, linked to horseradish
peroxidase (titre: 1:5000)
(Invitrogen, ThermoFisher
Scientific)

Anti-flag

Rabbit

1:4000

ThermoFisher

Goat α-rabbit, linked to horseradish

Scientific

peroxidase (titre: 1:5000)
(Invitrogen, ThermoFisher
Scientific)

Anti-GAPDH

Rabbit

1:2500

Abcam

Goat α-rabbit, linked to horseradish
peroxidase (titre: 1:5000)
(Invitrogen, ThermoFisher
Scientific)
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2.2.9 RNA extraction
To study the regulation of TARDBP mRNA levels in the presence of the individual RGNEF
constructs, RNA was extracted from transiently transfected HEK 293T cells in order to make
cDNA and quantify TARDBP mRNA expression levels. After gently washing the cells with PBS,
they were lysed by adding 400μl of Trizol (Ambion, ThermoFisher Scientific), homogenized and
incubated for 5 minutes at room temperature in order to allow for complete disassociation of
nucleoprotein complexes. Afterwards, 80μl of chloroform (ThermoFisher Scientific) was added
to the homogenate, vigorously mixed, incubated for 2 minutes at room temperature and
centrifuged for 15 minutes at 12,000g, 4°C. After separating the aqueous phase into a fresh tube,
the RNA was precipitated using 200μl of isopropanol, incubated for 10 minutes at room
temperature and centrifuged for 10 minutes at 12,000g, 4°C. The pelleted RNA was then washed
with 400μl 75% ethanol and centrifuged for 5 minutes at 7,500g, 4°C. After discarding the
supernatant, the pellet was dried at room temperature and resuspended in 20μl UltraPure RNAsefree distilled water (Invitrogen, ThermoFisher Scientific). The resuspended RNA in the pellet
was then incubated for 15 minutes at 60°C, quantified using a Nanodrop (Nanodrop 1000,
ThermoFisher Scientific) and frozen at -80°C for storage.
2.2.10 Reverse transcription (RT)
The extracted RNA from HEK 293T transiently transfected cells was reverse transcribed using
the SuperScript II Reverse Transcriptase system (Invitrogen, ThermoFisher Scientific). First, 2μg
of total RNA was incubated for 15 minutes at room temperature with 2μl of DNAse I (1U/μl)
(Invitrogen, ThermoFisher Scientific) and 2μl of 10X DNAse I Buffer in 20μl Ultrapure RNAsefree distilled water (Invitrogen, ThermoFisher Scientific). 2μl of 25mM EDTA was then added to
the DNAse treated RNA and incubated for 10 minutes at 65°C. Afterwards, 1μl of random
primers (3μg/μl) (Invitrogen, ThermoFisher Scientific) was added, incubated for 5 minutes at
70°C and immediately placed on ice. Subsequently, 8μl of 5X first strand buffer, 1μl of 25mM
dNTPs, 1μl of RNAseOUT ribonuclease inhibitor (40U/μl) (Invitrogen, ThermoFisher
Scientific), 0.5μl of 100mM DTT, 5.5μl of Ultrapure RNAse-free distilled water and lastly 1μl of
SuperScript Reverse Transcriptase (200U/μl) were added to the DNAse treated RNA, incubated
for 90 minutes at 42°C and for 15 minutes at 70°C afterwards. After the last incubation, the
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cDNA was placed on ice until it was ready to use for the PCR reaction or kept at -80°C for
storage.
2.2.11 Polymerase chain reaction (PCR)
The PCR reactions were performed using the Platinum Taq DNA polymerase (Invitrogen,
ThermoFisher Scientific), TARDBP primers to quantify the expression of TARDBP mRNA and
the 18S internal standard (QuantumRNA Universal 18S Internal Standard, Invitrogen,
ThermoFisher Scientific) used as an internal control for quantitative RNA analysis. The PCR
master mix used to amplify the cDNA and the incubation reactions performed on a thermal
cycler (Bio-Rad) are listed in Table 5, while the list of primers used for the quantitative RNA
analysis of TARDBP expression is detailed in Table 6. The PCR products were run on an agarose
gel containing 1% of ultrapure agarose dissolved in 1X Tris-acetate-EDTA (TAE) buffer and
RedSafe reactive (iNtRON Biotechnologies) at a 5μl:100ml ratio. The samples with 5X Orange
G loading buffer were then loaded on the gel in a wide mini-sub cell GT system (Bio-Rad) and
run at 100V for 60 minutes. The gel was observed under UV light and 1Kb plus molecular ruler
(Bio-Rad) was used to detect the amplicons from the PCR reaction.
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cycler

PCR incubation protocol in a thermal

PCR mix

Table 5. PCR master mix components and incubation protocol in a thermal cycler.
Reactive

Volume

10X PCR Buffer

5μl

50mM MgCl2

1μl

2.5mM dNTPs (each)

5μl

10μM Primers

1.2μl

18S Primer:Competimer (ratio 2:8)

0.2μl:0.8μl

cDNA

2μl

Taq Polymerase

0.2μl

Ultrapure RNAse-free distilled water

Up to 50μl

Stage 1

1 cycle

94°C

3 minutes

Stage 2

28 cycles

94°C

30 seconds

62°C

30 seconds

72°C

30 seconds

Stage 3

1 cycle

72°C

5minutes

Stage 4

1 cycle

4°C

∞

* Stage 1= initial denaturation; Stage 2 = Denaturation, Annealing, Extension; Stage 3 = Final
extension; Stage 4 = Hold

Table 6. Primers used in PCR to quantify TARDBP mRNA in transiently transfected HEK 293T
cells.
Name

Forward or

DNA sequence (5’ to 3’)

Reverse primers
TDP-43

Forward

5’ CAAAGCCATTCAGGGCCTTTGCC 3’

Reverse

5’ GATGCTGATCCCCAACCAATTGCT 3’
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2.2.12 Generation of transgenic flies
The transgenic flies used for the immunohistochemistry analysis were generated using the
GAL4/UAS system (Drosophila Genomic Resource Center). The driver strain parent line
contains transgenes that express the yeast GAL4 transcription factor in tissue-specific pattern
Elav, pan-neuronal. The responder parent line express target genes, TARDBP and LeuR, sensitive
to GAL4 transcription factor. The flies generated from crossing the responder and driver parent
lines express target genes in a tissue specific pattern (Fig. 7). Single transgenic flies Elav-TDP43 and double transgenic flies Elav-LeuR242;TDP-43 were previously characterized by C.
Droppelmann and B. Withers using genomic analysis (Droppelmann et al., unpublished)
(Withers, MSc Thesis). Fly stocks were maintained per standard procedures (Bloomington
Drosophila Stock Center) and their food was provided by Dr Kramer’s lab according to the
standard fly food recipe (water, yeast, soy fluor, yellow cornmeal, agar, light corn syrup,
propionic acid). Flies were raised in 25°C, 70% humidity chambers.
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Driver Strain Parent

Responder Parent

GAL4
GAL4

Tissue specific
promoter

Human gene

Sensitive
promoter

Elav à pan-neuronal

TARDBP
LeuR

Figure 7. Scheme of the GAL4/UAS system used to generate transgenic drosophila
melanogaster Elav-LeuR242;TDP-43 and Elav-TDP-43.

42

2.2.13 Fly fixation
To analyze the brain and eye tissue of transgenic drosophila melanogaster expressing TDP-43
and LeuR242, immunohistochemistry (IHC) was performed on paraffin embedded sections of
adult flies following the fixation protocol from the Shcherbata group (Kucherenko, et al., 2010).
Whole flies in collars were first incubated in Carnoy’s solution containing absolute ethanol,
chloroform and glacial acetic acid 6:3:1 ratio, overnight at 4°C. The flies in Carnoy’s solution
were then dehydrated by incubating them in 40% ethanol for 20 minutes, 70% for 20 minutes
and twice in 100% ethanol for 10 minutes each. Afterwards, they were incubated in
methylbenzoate (MB) and MB with paraffin solution, 1:1 ratio, for 30 minutes each at 60°C
following which they were incubated twice in paraffin solution for 60 minutes each at 60°C. The
flies in paraffin were then allowed to solidify at room temperature overnight before proceeding
to cutting the paraffin-embedded flies into 7μm sections in the Pathology Core facility (Robarts
Research Institute).
2.2.14 Immunohistochemistry (IHC)
For deparaffinizing and rehydrating, the slide sections of the fly brain and eye tissue were first
warmed on a slide warmer at 60°C for 30 minutes, then sequentially immersed in xylenes for 15
minutes, xylenes:ethanol (1:1 ratio) for 10 minutes, 100% ethanol, 95% ethanol, 70% ethanol,
50% ethanol and Millipore water for 5 minutes each, all at room temperature. Afterwards, the
slides were incubated in citrate -EDTA buffer pH 6.2, containing 10mM citric acid, 2mM EDTA
and 0.05% Tween-20, at 100°C for 30 minutes. This antigen retrieval buffer was designed to
break the protein crosslinks and therefore expose the antigens and epitopes in the paraffin
embedded tissue sections. Afterwards, the slides were incubated for 60 minutes at room
temperature in PBS pH 7.2 blocking solution with 5% BSA and 0.3% Triton-X 100, following
which they were incubated with primary antibodies at 4°C overnight in a humidifying chamber.
After primary antibody incubation, they were washed three times with PBS pH 7.2 for 5 minutes
each and then incubated with Alexa Fluor secondary antibodies for 60 minutes at room
temperature in a humidifying chamber. The dilutions used for primary and secondary antibodies
are indicated in table 7. The slides were then washed three times with PBS pH 7.2 and to
visualize nuclei the slides were incubated with 1μg/ml DAPI for 3 minutes. This incubation was
followed with three consecutive washes with Millipore water following which the slides were
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incubated with an autofluorescence quenching kit (Vector TrueVIEW, Vector Labs) for 4
minutes at room temperature. The slides were then washed and left to dry overnight at room
temperature. Once dry, coverslips were mounted to the slides using a fluorescent mounting
media (Dako). All the slides were then examined using an SP8 Lightening Confocal microscopy
system (Leica Microsystems Inc.) and visualized using the LAS X software (Leica
Microsystems Inc.)
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Table 7. Antibodies used for IHC experiments
Primary

Species

Dilution Manufacturer Secondary antibody

Rabbit

1:500

antibody
Anti-TDP-43

ProteinTech

Donkey α-rabbit ALEXA fluor
555nm (titre: 1:200) (Invitrogen,
ThermoFisher Scientific)

Anti-flag

Goat

1:400

ThermoFisher

Donkey α-rabbit, ALEXA fluor

Scientific

488nm (titre: 1:200) (Invitrogen,
ThermoFisher Scientific)
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2.2.15 Statistical analysis
The statistical analysis in aim 2 was undertaken using GaphPad Prism 8.3 (GraphPad software
Inc.). Student’s t-test was used when comparing two groups: the control group transfected with
the empty vector was compared to the experimental group transfected with the various constructs
of RGNEF. Statistical analysis was generated and reported as the mean ± (standard deviation)
SD of the mean and they were considered to be statistically significant when p<0.05.
Experiments were carried out in triplicate.
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Chapter 3
3. Experimental Results
3.1 Crosslink IPs in transiently transfected cells
Our lab had previously observed a potential interaction between RGNEF and TDP-43 in vitro
HEK 293T and in vivo through observing co-aggregation of both proteins in spinal motor
neurons of ALS patients (Keller, et al., 2012). Because of the presence of an atypical leucine rich
motif (LRR motif) in the amino-terminal region of RGNEF and given the role of other LRR
motifs in protein-protein interaction (Kobe & Deisenhofer, 1995), we postulated that the aminoterminal region of RGNEF is a critical domain mediating the interaction of RGNEF with TDP43. This postulate was further supported by the observation that within the amino-terminal region
of RGNEF, a 242 amino acid segment containing the LRR motif (LeuR242) (Fig. 8A) forms a
high molecular weight complex of proteins with TDP-43 in HEK 293T cells (Droppelmann,
Campos-Melo, Moszczynski, Amzil, & Strong, 2019).
As illustrated in figure 8, LeuR242 is predicted to contain an Ankyrin (ANK) repeat domain
between the amino-acids 162 and 229 in the amino-terminal region (Fig. 8A). The ANK repeats
are one of the most abundant protein classes in protein-protein interaction and are involved in
numerous physiological processes including transcriptional regulation (Li, Mahajan, & Tsai,
2006). The role of ANK in protein-protein interaction and its localization as part of the LeuR242
suggests that the ANK domain could be a good candidate for the minimal region involved in the
interaction between RGNEF and TDP-43. To determine if this was the case, we examined using
cross-linking studies the ability of various flag-tagged constructs containing either LeuR242 (and
thus containing both the LRR and ANK domain), LeuR110 (amino acids 97 through 206
containing only LRR), or ANK (amino acids 162 – 229 and thus containing only ANK as a small
C-terminus fragment of LRR) (Fig. 8A) to interact with myc-tagged TDP-43. The structure
prediction of LeuR110 and ANK with the flag-tag was conserved which would not affect the coaggregation of each sequence with TDP-43.
To determine the presence of protein-protein interaction between TDP-43 and LeuR in vitro,
protein lysates from transiently transfected HEK 293T cells with myc-tagged TDP-43 and flag-
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tagged LeuR110 were used in a chemical DTSSP crosslinking experiment. This water soluble
crosslinker is characterized by central disulfide bond sensitive to reducing conditions and its
amine-reactive N-hydroxysulfosuccinimide esters at each end of a 12Å spacer arm that react to
primary amines and form stable bonds at pH 7-9. While the use of this crosslinker might nonspecifically pull-down other proteins through their amine-reactive-NHS ester ends around the
12Å spacer arm, the following immunoprecipitation experiment using a monoclonal antibody
increases the specificity to our protein of interest TDP-43-myc. After running the
immunoprecipitation pulling down myc-tagged proteins and the western blot detecting flagtagged proteins, we observed a high molecular weight complex (>250 KDa) containing myctagged TDP-43 in the presence of flag-tagged LeuR110 in non-reducing conditions. However, in
the presence of ß-mercaptoethanol, causing the di-sulfide bond of DTSSP to be cleaved, we
detected the presence of a low molecular weight protein (50kDa) (Fig. 8B). These results suggest
that the cleavage of the disulfide bond resulted in breaking the complex of proteins in which only
the flag-tagged protein was detected in the western blot. While the expected size of flag-LeuR110
is 12kDa, the detected band size in reducing conditions is 40kDa suggesting that while the
disulfide bond of DTSSP was cleaved, the flag-LeuR110 pulled down was still in a complex with
other proteins which would explain the difference between the expected and detected protein
band size.
To determine if the ANK domain participates in the formation of this high molecular weight
complex, we conducted the same crosslink IP using protein lysates from transiently transfected
cells with myc-tagged TDP-43 and flag-tagged ANK. Given the role of the ANK domain in
protein-protein interaction, we expected the presence of an interaction between ANK and TDP43. However, we observed no interaction between flag-tagged ANK and myc-tagged TDP-43
suggesting that the ANK binding domain does not play a role in the interaction between RGNEF
and TDP-43.
This series of experiments indicated that the 110 amino-acids fragment contained in the
LeuR region is sufficient for the interaction with TDP-43. In addition, given that the observed
molecular weight of the immunoprecipitant was > 250 kDA, significantly greater than that which
would have been predicted if LeuR110 interacted alone with TDP-43 (Fig. 8B), we postulated that
this interaction is within a larger complex of proteins. These results suggest that the LeuR110
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sequence contained in the amino-terminal region of RGNEF is the minimal domain of the protein
required for its indirect interaction with TDP-43.
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Figure 8. flag-LeuR110 and TDP-43-myc form a complex after DTSSP crosslinking
treatment while flag-ANK and TDP-43-myc do not form a complex. (A) Scheme showing
LeuR242 previously characterized in the interacting complex with TDP-43 and the LeuR region
flag-tagged constructs used to study the minimal domain of interaction with TDP-43: LeuR110
containing only the LRR (amino acids 97-207), ANK containing only the ANK repeat, including
a small fragment of the C-terminal LRR (amino acids 162-229). (B) Using DTSSP as the
crosslinking agent, we observed a high molecular weight complex between myc-tagged TDP-43
and flag-tagged LeuR110. This complex could be dissociated with β-mercaptoethanol. The
immunoprecipitants were run on a gradient (4-20%) SDS-PAGE gel and detected using
immunoblotting probed with anti-flag antibody (1:4000). (C) In contrast, we failed to observe
any interaction between flag-tagged ANK and myc-tagged TDP-43.
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3.2 Endogenous expression of TDP-43 in HEK 293T cells in the presence of
RGNEF constructs
To determine the critical domains of RGNEF involved in the regulation of TDP-43, the
endogenous expression of TDP-43 was measured in transiently transfected HEK 293T cells.
HEK 293T cell line was chosen because of its amenability to transfection, its neuronal-like
properties (Shaw, Morse, Arabat, & Graham, 2002) and its endogenous expression of TDP-43.
The plasmids used were myc-tagged: full length RGNEF, RΔLeuR or RΔCOOH. The control
plasmid used was a pcDNA3.1 empty vector. The first experiment conducted was to determine
the effect of RGNEF on the endogenous expression levels of TDP-43 using a western blot. The
goal was to determine the endogenous levels of expression of TDP-43 in the presence of various
constructs of RGNEF. In addition to protein levels, the expression of TARDBP mRNA
expression levels was also analyzed in the presence of different RGNEF constructs. Finally,
given the role of RGNEF as a destabilizing factor of NEFL through its 3’untranslated region
(UTR) (Droppelmann, Keller, Campos-Melo, Volkening, & Strong, 2013), the role of this region
on the TARDBP mRNA stability was analyzed using luciferase reporter assay in the presence of
full length RGNEF. The 3’UTR of the ALS-associated gene, FUS was used as control.
3.2.1 Effect of various RGNEF constructs on the endogenous expression of TDP-43 in
HEK 293T
Previously our lab has examined the effect of RGNEF on the expression levels of endogenous
NFL in HEK 293T cells (Droppelmann, Keller, Campos-Melo, Volkening, & Strong, 2013). We
observed that in the presence of full length RGNEF, the endogenous levels of NFL decreased
significantly. The effect of RGNEF on NFL expression levels could be normalized in the
presence of RGNEF knockdown.
In order to determine whether a similar regulatory effect of RGNEF is present in relationship
to TDP-43 and to determine if there is a minimal domain involved in its regulation, HEK 293T
cells were transiently transfected with a pcDNA3.1 empty vector and three different myc-tagged
constructs full length RGNEF-myc, RΔLeuR-myc and RΔCOOH-myc (Fig. 9A). To do so,
protein extracts from cell lysates were generated and anti-TDP-43, anti-myc, antibodies for
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western blotting were used to quantify the endogenous expression of TDP-43. The expression
levels of TDP-43 were normalized to the housekeeping protein GAPDH and each group from
cell lysates transfected with RGNEF constructs, was compared to the control transfection
containing an empty vector. All studies were done in triplicate.
We observed that the expression levels of TDP-43 were significantly decreased in the
presence of full length RGNEF and RΔCOOH (fold change: -0.184±0.042; -0.236±0.039; both
p<0.05; respectively, Fig. 9C). However, in the absence of the amino-terminal region, RΔLeuR,
there was no significant change in the levels of expression of endogenous TDP-43 in the cells
(Fig. 9B-C). These results suggest that LeuR242 of RGNEF, is involved in the down-regulation of
endogenous TDP-43 expression levels of the protein in HEK 293T cells in normal conditions.
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Figure 9. TDP-43 protein expression levels are decreased in HEK 293T transfected cells
expressing full length RGNEF. (A) Aligned protein sequences of RGNEF constructs (RGNEF
full length, RΔLeuR and RΔCOOH) used to study the effect of putative regions of RGNEF on
the endogenous expression of TDP-43 in vitro. --- indicates deleted amino acids in RΔLeuR and
RΔCOOH. Green indicated the leucine rich domain, yellow indicates the cysteine-rich Znbinding domain red indicates the Dbl homology domain (DH), blue indicates the Pleckstrin
homology domain (PH) and orange indicates the RNA-binding domain. (B) The expression level
of TDP-43 protein was analyzed by western blotting in HEK 293T cells transfected with either
full length RGNEF, RΔLeuR or RΔCOOH, using the endogenous levels of TDP-43 as the
control. (C) Expression levels of TDP-43 protein were quantified comparing the TDP-43 protein
levels between the control and HEK 293T RGNEF-full length, RΔLeuR and RΔCOOH cells. A
significant reduction in TDP-43 protein levels was only observed in RGNEF-full length and
RΔCOOH transfected cells. (n=3independent experiments, the results are presented as mean,
standard deviation of the mean. A student t-test was performed; p-value significant: p<0.05).
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3.2.2 Effect of RGNEF constructs on the endogenous expression of TARDBP mRNA in
HEK 293T cells
It has been previously reported that the murine homolog of RGNEF (p190RhoGEF) enhances the
stability of murine NEFL mRNA through a direct interaction within the hinge domain of NEFL
mRNA 3’UTR (Cañete-Soler, Wu, Zhai, Shamim, & Schlaepfer, 2001). In contrast, our lab
observed that RGNEF destabilizes human NEFL mRNA in HEK 293T and that this effect is
critically dependent on the presence of the N-terminus domain of RGNEF (Droppelmann, Keller,
Campos-Melo, Volkening, & Strong, 2013).
Given this and my previously described observation that RGNEF down-regulates the
expression of TDP-43 in vitro, we further examined the effect of RGNEF on the endogenous
levels of TARDBP mRNA. To do so, we undertook transient transfections in HEK 293T cells
using full length RGNEF or its other constructs (Fig. 10A).
The endogenous expression of TARDBP mRNA in transiently transfected HEK 293T cells
was normalized to the housekeeping gene GAPDH. Each group of transfected cells with full
length RGNEF and its constructs was compared to the control group transfected with an empty
vector. We observed that in the presence of full length RGNEF and its other constructs there was
no significant effect on the expression level of endogenous TARDBP mRNA (Fig. 10C).
Contrary to the significant reduction of endogenous TDP-43 protein levels observed in the
presence of full length RGNEF and RΔCOOH construct, there was no effect on the endogenous
expression of TARDBP transcript, which suggests that the down-regulation effect observed at the
protein level is not a result of a down-regulation of its transcript levels.
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Figure 10. TARDBP mRNA endogenous expression in the presence of RGNEF constructs.
(A) Schematic of the RGNEF constructs used in transiently transfected cells to evaluate the
effect of putative regions of RGNEF on the expression levels of endogenous TARDBP mRNA.
(B) The expression of TARDBP mRNA in HEK 293T RGNEF-full length, RΔLeuR and
RΔCOOH cells was analyzed by relative quantitative polymerase chain reaction (RT-PCR) and
compared with the amount of TARDBP mRNA in control cells. No significant difference was
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observed between the groups expressing RGNEF constructs and the control group. (C)
Expression levels of TARDBP mRNA were quantified comparing the TARDBP transcript levels
between the control and HEK 293T RGNEF-full length, RΔLeuR and RΔCOOH cells. No
significant effect was observed when comparing TARDBP mRNA of transfected cells with
RGENF constructs to control cells (n=3independent experiments, the results are presented as
mean, standard deviation of the mean. A student t-test was performed; ns: not significant, pvalue p>0.05).
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3.2.3 Regulation of TARDBP 3’UTR
As previously reported, RGNEF interacts directly with NEFL transcript through its 3’UTR
(Droppelmann, Keller, Campos-Melo, Volkening, & Strong, 2013). We had also observed that
RGNEF could interact with NEFL mRNA in human lumbar spinal cord homogenates (using
RNA-IP), but only in homogenates derived from ALS patients (Volkening, Leystra-Lantz, &
Strong, 2010).
In order to further explore the genesis of the reduction in TDP-43 protein levels in the
presence of RGNEF, having failed to observe a reduction in TARDBP mRNA levels in the
previous experiment, we next examined whether RGNEF has a destabilizing effect on TARDBP
mRNA. The 3’UTR of the ALS-associated gene, FUS was used as control. To do this, we used a
dual luciferase reporter assay measuring the effect of exogenous RGNEF-full length on the
luciferase activity when linked to the 3’UTR of either FUS or TARDBP. HEK 293T cells were
transiently transfected with a firefly luciferase pmirGLO linked to the 3’UTR of either FUS,
TARDBP mRNA or full length RGNEF (Fig. 11A). The controls used for normalizing the assay
were the pmirGLO and the pcDNA3.1 empty vector and the normalization of the assay was
calculated as previously described by our group in a comprehensive study using the luciferasebased reporter gene assay (Campos-Melo, Droppelmann, Volkening, & Strong, 2014).
In these experiments, we observed a significant down-regulation (-0.047±0.0036, p<0.05)
(Fig. 11B) in the relative luciferase activity of TARDBP 3’UTR in the presence of full length
RGNEF. However, we did not observe an effect on the relative luciferase activity of FUS 3’UTR
when exposed to RGNEF.
Our previous result from quantifying the endogenous expression of TARDBP mRNA
showed no significant effect on the endogenous expression of TARDBP mRNA in the presence
of full length RGNEF. However, the quantification of the endogenous expression of TDP-43
protein in the presence of full length RGNEF demonstrated a significant down-regulation when
compared to the control group which suggests that the loss of TDP-43 protein in the presence of
full length RGNEF is due to a direct destabilizing effect of RGNEF on the TARDP mRNA
3’UTR.
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Figure 11. Full length RGNEF destabilizes the luciferase activity of TARDBP 3’UTR. (A)
Schematic showing the constructs used in the assay: FUS 3’UTR or TARDBP 3’UTR linked
fireflyluciferase (fLuc) upstream and to renilla luciferase downstream; exogenous full length
RGNEF or pcDNA3.1 empty vector. (B) Reporter gene assay showing decreased normalized
luciferase activity in HEK 293T cells co-transfected with pcDNA-RGNEF-myc and pmirGLO
linked to the 3’ UTR of TARDBP or FUS mRNA. We observed a significant reduction of the
luciferase activity of TARDBP 3’ UTR in the presence of RGNEF-full length compared to the
luciferase activity of FUS 3’UTR. A t-test was performed to compare the effect of RGNEF on
FUS and TARDBP 3’UTRs. p-value (*) = p<0.05; ns = not significant.
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3.3 The expression of hTDP-43 and flag-LeuR242 in transgenic drosophila
melanogaster models.
To study the relationship between TDP-43 and LeuR of RGNEF, our lab in collaboration with Dr
Kramer’s lab developed drosophila melanogaster in vivo models expressing these particular
proteins. Preliminary results characterizing the lifespan, motor functions and eye degeneration in
double transgenic flies Elav-LeuR242;TDP-43 showed a significant improvement when compared
to single transgenic flies Elav-TDP-43 (Withers, MSc Thesis). While the expression of human
wild-type TDP-43 showed a dramatic reduction in survival and motor functions, in addition to
eye degeneration, the co-expression of human wild-type TDP-43 and LeuR242 showed a
significant improvement in the flies’ lifespan and, motor functions. Similar to our in vitro data
demonstrating the cytoprotective effect of the amino-terminal region of RGNEF against osmotic
stress in cells (Cheung, et al., 2017), the in vivo data suggests that the LeuR242 offers a protective
effect against TDP-43 toxicity in our drosophila melanogaster model (Withers, MSc Thesis).
We next directed our attention to exploring this effect of RGNEF and LeuR242 in reducing
the toxicity of TDP-43 in vivo. As has been described, we have observed that LeuR110 is able to
interact with TDP-43 through the formation of a high molecular weight complex. We have
shown that RGNEF induces a reduction in TDP-43 protein levels and that this effect is
dependent on the LRR contained within the N-terminus domain of RGNEF. And we have shown
that full length RGNEF interacts with the 3’UTR of TDP-43 to induce destabilization of the
firefly luciferase transcript. These in vitro data are strongly supportive of a direct effect of
RGNEF at both the protein and RNA level of TDP-43.
Given this, and to better understand the protective role of the LeuR242 region in mitigating the
TDP-43 toxicity observed in the flies, we studied the pathology of TDP-43 toxicity in the
absence or presence of LeuR242 using fluorescent immunohistochemistry (IHC) of the brain and
eye tissue of single and double transgenic flies. In the following experiments, the double
transgenic flies Elav-LeuR242;TDP-43 were generated using the LeuR242 construct only because
the fly study in the lab started before we determined the LeuR110 as the minimal domain of
interaction with TDP-43. Since the results from our in vitro study confirmed that the interaction
with TDP-43 is independent of the ANK domain contained in LeuR242 we used LeuR242 as a
surrogate for LeuR110 in the in vivo study. All the transgenic flies were generated using the
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GAL4/UAS system, in which human TDP-43 and flag-tagged LeuR242 were expressed in a tissue
specific manner. Both Elav-TDP-43 and Elav-LeuR242;TDP-43 fly models express their
transgenes in neurons.
In the images of the brain and eye tissue of transgenic flies, we observed the expression of
TDP-43 in aggregates. In the case of single transgenic flies Elav-TDP-43, these aggregates were
more condensed, and their size was bigger (Fig. 12C) when compared to TDP-43 aggregates in
double transgenic flies (Fig. 12F). In the Elav-LeuR242;TDP-43 flies we detected the presence of
higher number of dispersed punctate aggregates expressing TDP-43 in both the brain and eye
tissue (Fig. 12G-H), absent in the brain and eye tissue of single transgenic flies Elav-TDP-43
(Fig. 12D-E). The images from the tissue of Elav-LeuR242;TDP-43, looking into the expression
of flag-tagged LeuR242 and human TDP-43, showed that both proteins are expressed in
aggregates (Fig. 13E-F; I-J) where they colocalize (Fig. 13G-L).
This suggests that the co-aggregation of TDP-43 and the LeuR242 alongside the distribution
and shape of these aggregates are possible mechanisms of protection against TDP-43 toxicity in
these fly models.
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Figure 12. Confocal images show the localization of TDP-43 in the brain and eye tissue of
single and double transgenic flies. Immunofluorescence using anti-TDP-43 antibody,
visualized in red, shows the localization of TDP-43 in aggregates in single transgenic Elav-TDP43 and double transgenic Elav-LeuR242;TDP43 drosophila melanogaster. Panel (A) shows an
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overview of the brain and eye anatomy of Elav-LeuR242;TDP43 drosophila melanogaster. Scale
bar = 100µm. Panel (B) shows a negative control of TDP-43 staining of Elav-LeuR242;TDP-43
flies. Scale bar = 100µm. Panel (C) shows an overview of the brain and eye tissue of single
transgenic flies. Scale bar = 20μm. Panels (C and D) show the aggregation of TDP-43 in the
brain and eye tissue, respectively, of single transgenic flies. Scale bar = 2µm. Panel (E) shows an
overview of the brain and eye tissue of Elav-LeuR242;TDP43 transgenic flies. Scale bar = 20μm.
Panels (F and G) show the aggregation of TDP-43 in the brain and eye tissue, respectively, of
Elav-LeuR242;TDP43 transgenic flies. Scale bar = 2µm.
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Figure 13. flag-LeuR242 co-aggregates with TDP-43. Immunofluorescence using anti-flag
antibody visualized in green, and anti-TDP-43 antibody visualized in red, in the brain and eye
65

tissue of Elav-LeuR242;TDP-43 drosophila melanogaster. Panels (A and B) show an overview of
the brain and eye tissue of double transgenic flies with LeuR242 visualized in green, TDP-43
visualized in red and the panels (C and D) show the merge of TDP-43 and LeuR242 with their coaggregation. Scale bar = 20μm. Panels (E and F; I and J) show the co-aggregation (G and H; K
and L) of TDP-43 and LeuR242 in the brain and eye tissue, respectively, of double transgenic
flies. Scale bar = 5µm. Panels (M and N) are a magnification of inset boxes in panels (G and K)
respectively, and they show the co-aggregation of TDP-43 and LeuR242. Both TDP-43 and
LeuR242 co-aggregate in the brain and eye tissue of double transgenic flies with a distinctive
phenotype consisting of dispersed punctate aggregates. Scale bar = 1µm.
Panels (O and P) are negative controls for flag and TDP-43 staining respectively in ElavLeuR242;TDP-43 flies. Scale = 100μm.
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Chapter 4
4. Discussion
4.1 LeuR110 of RGNEF is critical for the interaction with TDP-43
While previous data demonstrated the co-aggregation of TDP-43 and RGNEF in motor neurons
of ALS patients and the interaction between the two proteins in vitro (Keller, et al., 2012), the
question remains what domain of RGNEF is critical for the interaction. More recent in vitro data
from our group showed the presence of an interaction between TDP-43 and LeuR242 contained in
the amino-terminal end of RGNEF (Droppelmann, Campos-Melo, Moszczynski, Amzil, &
Strong, 2019). The presence of LeuR110 and ANK (Fig. 14A-B) in the LeuR242 sequence and
their role in protein-protein interaction led us to the hypothesis that there is a functional and
biochemical interplay between RGNEF and TDP-43 where the interaction between these two
proteins is regulated by a minimal domain contained within the LeuR region of RGNEF.
Here were report the presence of high molecular weight complex composed of flagLeuR110 and TDP-43-myc through a crosslink experiment using a chemical crosslinker, DTSSP,
sensitive to reducing conditions. In non-reducing conditions, the size of the detected complex
(>250kDa) suggests that in addition to TDP-43 and LeuR110, other proteins are present in the
complex. In reducing conditions, by breaking the disulfide bond of DTSSP, the high molecular
weight complex was dissociated and only a smaller band was detected at approximately 40kDa
which suggests that the interaction between LeuR110 and TDP-43 in the complex has been
broken.
A software analysis (Fig. 14B-C) of the full length RGNEF predicts the presence of an
ANK repeat between the amino-acids 162 and 229 contained in the LeuR242 sequence. Given the
role of the ANK in protein-protein interaction (Li, Mahajan, & Tsai, 2006), we also investigated
the role of ANK in the interaction with TDP-43. However, under the same experimental
conditions, we were unable to immunoprecipitate the complex containing ANK and TDP-43.
These findings suggest that within the LeuR242 sequence, LeuR110 (amino acids 97 through 206)
is the minimal domain of RGNEF required for the interaction with TDP-43.
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The leucine-rich repeats are evolutionary conserved in proteins and play a central role in
protein-protein interaction (Kobe & Deisenhofer, 1995). Their secondary structure consisting of
repeated structural units, such as α-helix, 310-helix and β-turns, is critical for their role in proteinprotein interaction (Kobe & Kajava, 2000). The unique structure of LeuR110 consisting of eight
consecutive α-helices (amino acids 97 through 206) (Fig. 14A), is consistent with the role of
LeuR110 as the minimal domain of RGNEF involved in the interaction with TDP-43. However,
whether the interaction between TDP-43 and RGNEF is direct or indirect remains unknown.
While our data demonstrate that within RGNEF, LeuR110 is the minimal domain required for the
interaction with TDP-43, in which the proteins are interacting in a complex involving at least
another protein, the nature of the interaction is not clear.
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Figure 14. Prediction of secondary structure of LeuR110 and ANK domains of RGNEF. (A)
Secondary structure of LeuR110 showing the presence of eight α-helices (amino acids 97 through
206). (B) Secondary structure ANK showing the presence of five α-helices (amino acids 166
through 221). The model was created using I-Tasser (http://zhanglab.ccmb.med.umich.edu/ITASSER/). (C) Aligned protein sequences of LeuR110 (amino acids 97 through 206) and ANK
(amino acids 162 – 229 a small C-terminus fragment of LRR). -- indicates deleted amino acids in
ANK; green indicates the leucine rich domain (amino acids 97 through 206).
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4.2 The co-aggregation of LeuR and TDP-43 in transgenic drosophila
melanogaster models.....................................
In human tissue, our lab has previously characterized the co-aggregation of RGNEF and TDP-43
in motor neurons of ALS patients (Keller, et al., 2012). In vitro data showed that LeuR242
interacts with TDP-43 (Droppelmann, Campos-Melo, Moszczynski, Amzil, & Strong, 2019). To
investigate the functional and biochemical interplay between TDP-43 and RGNEF, our lab
developed drosophila melanogaster transgenic models co-expressing human TDP-43 and flagLeuR242 in neuronal cells. Here, by comparing the pathology of TDP-43 in the presence or
absence of LeuR242 in neuronal cells, we noted that TDP-43 is expressed in neuronal aggregates
both in the eye and brain tissue. By comparing the brain and eye tissue of Elav-TDP43 flies to
Elav-flag-LeuR242, we observed a difference in the aggregates’ phenotype containing TDP-43. In
the presence of LeuR242 there is co-aggregation of TDP-43 with LeuR242 in neurons of the brain
and eye tissue where the two proteins co-aggregate in small aggregates. These results suggest
that LeuR242 offers a cytoprotective effect against TDP-43 pathogenicity by sequestering toxic
TDP-43 in aggregates. In addition to the qualitative data from our histological analysis,
comparing the aggregates’ phenotype in the absence or presence of LeuR242, a quantitative study
comparing the size of the aggregates containing TDP-43 in the brain and eye tissue of single
transgenic versus double transgenic flies would help elucidate the formation of these inclusions
act as a protective mechanism against TDP-43 toxicity. A crosslink IP experiment using DTSPP
crosslinker and protein lysates from Elav-LeuR242;TDP-43 double transgenic flies should be used
to correlate our in vivo observations to the interaction of LeuR with TDP-43 in vitro.
Previous data from the literature demonstrated the toxic effect of TDP-43, resulting in a
significant loss of motor functions and a decrease in the flies’ lifespan (Voigt, et al., 2010)
(Hanson, Wassarman, & Tibbetts, 2010) (Langellotti, et al., 2016) which led to the possibility of
investigating genetic modifiers of TDP-43 and therefore possible therapeutic targets.
RGNEF has previously been described to form intracellular inclusions in motor neurons of both
familial and sporadic ALS patients (Droppelmann, Keller, Campos-Melo, Volkening, & Strong,
2013). The LeuR242 has been shown to have a cytoprotective effect under osmotic stress
conditions (Cheung, et al., 2017).
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Previously, RGNEF has been identified as an ALS-protein where frameshift mutations in
ARHGEF28 encoding RGNEF are predicted to generate truncated proteins containing the LeuR
region (Droppelmann, et al., 2013). However, our in vivo model suggests that the expression of
the LeuR242 offers a protective effect against TDP-43 toxicity (Withers, MSc Thesis). The data
from a study comparing Elav-TDP-43 flies and D42-TDP-43 to Elav-flag-LeuR242;TDP-43 flies
and D42-flag-LeuR242;TDP-43 expressing their transgenes in neuronal cells and motor neurons
respectively illustrate the role of LeuR242 as a modifier of TDP-43 toxicity in vivo. The coexpression of LeuR242 and TDP-43 resulted in a significant increase in the lifespan and motor
functions of double transgenic flies compared to the flies expressing TDP-43 alone. These
observations alongside the pathology of TDP-43 in the presence LeuR242 in this study reinforces
the role of LeuR242 as a modifier of TDP-43 toxicity, providing a protective effect in neurons and
motor neurons. Additionally, the recent data, demontrating the co-aggregation of LeuR with
TDP-43 in a high molecular weight complex suggest that the protective effect of LeuR against
TDP-43 toxicity involves at least an additional protein. However, the mechanism underlying the
protective role LeuR242 against TDP-43 toxicity remains unclear.

4.3 RGNEF plays a role in the regulation of ALS-associated protein TDP-43 in
vitro
For the in vitro study, HEK 293T cell line was chosen because of its neuronal-like properties and
amenability to transfection. Unlike the human neuroblastoma cell line SH-SY5Y in which the
efficiency of transient transfection is very low, HEK 293T cells offer a high transfection
efficiency and transiently maintain a high copy number of transfected plasmid DNA.
Additionally, given the endogenous expression of RGNEF’s murine homolog p190rhoGEF in
murine cell line neuro-2a and its stabilizing effect on murine NEFL mRNA (Lin, Zhai, &
Schlaepfer, 2005), only HEK 293T cells were used to study the role of RGNEF in the regulation
of endogenous TDP-43.
RGNEF has previously been reported as destabilizing NEFL mRNA through the
interaction of RGNEF with NEFL mRNA 3’UTR (Droppelmann, Keller, Campos-Melo,
Volkening, & Strong, 2013). Here we report the effect of RGNEF on the endogenous expression
of TDP-43 in HEK 293T cells.
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While the endogenous expression of TARDBP transcript in cells is not affected by the
expression of full length RGNEF, the luciferase assay results demonstrate the destabilizing effect
of full length RGNEF on TARDBP mRNA through its 3’UTR. For my thesis, the endogenous
TARDBP mRNA expression levels were measured using RT-PCR only. While a more sensitive
experiment was being set using real-time qRT-PCR, the lab and the university went under
lockdown for a few months because of the pandemic and consequently only the RT-PCR
experiment was completed. At the protein level, we note the down-regulatory effect of full length
RGNEF and RΔCOOH on the expression levels of TDP-43 protein in cells. However, in the
absence of LeuR242 demonstrated by the expression levels of TDP-43 in HEK 293T cells
transfected with RΔLeuR, there was no significant effect on the regulation of TDP-43 when
compared to controls. Through a dual reporter luciferase assay we measured the effect of full
length RGNEF only on the luciferase activity of TARDBP mRNA 3’UTR, however our
conclusions remain incomplete. In addition to full length RGNEF, we need to account for the
effect of RΔLeuR and RΔCOOH on TARDBP mRNA 3’UTR stability under the same
experimental conditions.
Early studies focusing on the role of RGNEF’s murine homologue p190RhoGEF in vivo,
identified the protein’s interactive properties and its role in post-transcriptional regulation of
NEFL mRNA (Cañete-Soler, Wu, Zhai, Shamim, & Schlaepfer, 2001). Using transgenic mice
expressing human NEFL mRNA, Schlaepfer and colleagues showed that the interaction between
the C-terminal domain of p190RhoGEF and the 3’UTR region of NEFL mRNA resulted in the
alteration of NEFL mRNA stability which in turn led to the post-transcriptional regulation of
murine NFL protein.
With the available data confirming the interaction of TDP-43 with LeuR110 and LeuR242,
these findings suggest a regulatory mechanism by which the interaction of TDP-43 with RGNEF
through the LeuR region results in the destabilization of TARDBP mRNA 3’UTR and
consequently in the down-regulation of endogenous expression of TDP-43.
The C-terminal region of TDP-43 has been implicated in numerous protein-protein
interactions (Buratti, et al., 2005) in addition to its role in the autoregulation of its protein levels
through TARDBP mRNA 3’UTR (Ayala, et al., 2011) (Bhardwaj, Myers, Buratti, & Baralle,
2013). In vitro data showed that the interaction of C-terminal region of TDP-43 protein with
TARDBP mRNA 3’UTR resulted in a decreased level of expression of TDP-43. Given our data
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demonstrating the interaction between LeuR110 and TDP-43 alongside the destabilizing effect of
RGNEF over TARDBP mRNA 3’UTR and the down-regulation of endogenous levels of TDP-43
in the presence of the LeuR region of RGNEF, it is possible that by binding the 3’UTR of
TARDBP mRNA, the LeuR region of RGNEF activates the TDP-43 negative feedback loop
which in turn leads to the down-regulation of its protein levels.
Our finding also suggests a possible mechanism by which LeuR acts as a modifier of
pathogenic TDP-43 in our in vivo model. The co-aggregation of LeuR242 with cytoplasmic TDP43 in neuronal cells leads to the down-regulation its expression levels which in turn results in
reducing the toxic effect of TDP-43 observed in single transgenic flies Elav-TDP-43.

4.4 Future directions
While our in vitro results identify the LeuR110 as the minimal domain of RGNEF required for the
interaction with TDP-43, the mechanism by which this interaction occurs remains unclear. Here
we report that the interaction of TDP-43 and LeuR110 is within a high molecular weight complex
which suggests the presence of at least another protein in the complex. By using mass
spectrometry on the purified IP complex, it will be possible to identify the proteins contained
within this interactive complex therefore elucidating the mechanism by which TDP-43 and
LeuR110 are brought into the complex. Still the question remains, is the interaction between TDP43 and LeuR110 direct or indirect? To answer the question, a crystal structural analysis of this
protein-protein interaction is necessary. By elucidating the atomic structure of the protein-protein
interaction through X-ray crystallography and by identifying the proteins contained in the
complex, we can determine the nature of the interaction between TDP-43 and LeuR110.
Our in vivo data focusing on the pathology of TDP-43 in the presence of LeuR242, provides
us with additional evidence regarding the protective effect of LeuR242 where it co-aggregates
with TDP-43. Additional experiments, analyzing the pathology of TDP-43 in the absence of
LeuR alongside a biochemical study of the co-aggregation of TDP-43 and LeuR242 are necessary
to determine if other putative regions of RGNEF act as a modifier of TDP-43 pathogenicity.
While our findings help elucidate the effect of LeuR242 over the endogenous expression of
TDP-43, our experiments were limited to normal conditions. Given the cytoprotective role of
LeuR242 in cells under osmotic stress and its protective effect against TDP-43 toxicity in vivo, it
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is necessary to investigate the effect of the putative regions of RGNEF beyond LeuR242 under
osmotic, metabolic and lactic stress conditions. Additionally, while in normal conditions, TDP43 is mainly localized in the nucleus where it regulates numerous RNA processing pathways
(Polymenidou, et al., 2011), under stress conditions TDP-43 aggregates in the cytoplasm
resulting in cellular toxicity. Therefore, by analyzing the localization of RGNEF and TDP-43 in
the cells, in addition to evaluating the effect putative regions of RGNEF on TARDBP mRNA and
TDP-43, we could better understand how RGNEF acts as modifier of TDP-43.
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